Improved cell lysis method, reagents, and kit for viral vector release and production

A novel lysis reagent with defined buffer and salt concentrations simplifies and enhances viral vector release from cell cultures, addressing inefficiencies in current methods by improving yield and safety, and enabling scalable production.

KR1020260161613APending Publication Date: 2026-11-09SARTORIUS STEDIM BIOTECH GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020267033519
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-11
Filing Date
2025-03-10
Publication Date
2026-11-09

AI Technical Summary

Technical Problem

Current methods for releasing viral vectors from cell cultures are inefficient, labor-intensive, and difficult to scale up, often requiring specialized equipment and hazardous chemicals, leading to high production costs and impurity issues.

Method used

A method involving a lysis reagent with specific buffer and salt concentrations (0.01 M to 3 M and 0.01 M to 5 M, respectively) is used to release viral vectors without separating cells from the surrounding liquid, ensuring high yield and stability, and can be applied to various samples, including cell culture media and pellets.

Benefits of technology

The method enhances viral vector release efficiency, improves yield, and simplifies the process by eliminating the need for cell separation, while ensuring safety and scalability, and maintaining vector integrity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCT00014_ABST
    Figure PCT00014_ABST
Patent Text Reader

Abstract

The present invention relates to a method for releasing a viral vector from a cell culture, wherein the cells of the cell culture do not need to be separated from the surrounding liquid before the cell culture is brought into contact with a lysis reagent. The present invention also relates to a method for producing a viral vector comprising the step of releasing a viral vector from a cell culture according to the disclosed method for releasing a viral vector from a cell culture. The present invention also relates to a cell lysis reagent for releasing a viral vector from a cell culture. The present invention also relates to a kit for releasing a viral vector from a cell culture, wherein the kit comprises a container containing the disclosed cell lysis reagent.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present disclosure generally relates to the field of viral vector production. In particular, the present invention relates to a method for releasing a viral vector from a cell culture, wherein the cell culture does not require separating the cells of the cell culture from the surrounding liquid before contacting the cell culture with a lysis reagent. The present invention also relates to a method for producing a viral vector, particularly comprising the step of releasing a viral vector from a cell culture according to the disclosed method for releasing a viral vector from a cell culture. The present invention also relates to a cell lysis reagent for releasing a viral vector from a cell culture. The present invention also relates to a kit for releasing a viral vector from a cell culture, wherein the kit comprises a container containing the disclosed cell lysis reagent. Background Technology

[0002] Technical field of invention

[0003] The present disclosure generally relates to the field of viral vector production. In particular, the present invention relates to a method for releasing a viral vector from a cell culture, wherein the cell culture does not require separating the cells of the cell culture from the surrounding liquid before contacting the cell culture with a lysis reagent. The present invention also relates to a method for producing a viral vector, particularly comprising the step of releasing a viral vector from a cell culture according to the disclosed method for releasing a viral vector from a cell culture. The present invention also relates to a cell lysis reagent for releasing a viral vector from a cell culture. The present invention also relates to a kit for releasing a viral vector from a cell culture, wherein the kit comprises a container containing the disclosed cell lysis reagent.

[0004] Technology forming the background of the invention

[0005] Viral vectors have been developed as an important modality of gene therapy over the past few years, and gene therapy enables the repair of dysfunctional DNA sequences or the introduction of compensatory changes that restore normal physiological functions of cells. Well-known examples of viral vectors from which recombinant viral vectors are derived include enveloped viruses, e.g., retroviruses, lentiviruses, Sendai viruses, and herpes viruses, and non-enveloped viruses, e.g., adenoviruses and adeno-associated viruses (hereinafter referred to as AAVs). Gene therapy using gamma retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses (AAVs) is attractive because of the innate ability of viruses to enter cells and deliver genetic material. Specifically, recombinant AAV (rAAV)-based vectors are ideal for gene therapy applications, and AAV vector-mediated gene delivery has recently led to drug approvals for the treatment of, for example, hereditary blindness and spinal muscular atrophy, and long-term therapeutic effects have also been achieved for other rare diseases including hemophilia and Duchenne muscular dystrophy.

[0006] Recombinant viral vectors based on AAV are in vivo ( in vivoAAV is an excellent vector for gene therapy. AAV can infect a wide variety of cells, including human cells, blood cells, muscle cells, and nerve cells, as well as fully differentiated, non-dividing cells. The wild-type AAV genome contains Rep and Cap genes with inverted terminal repeats (ITRs) located on both sides; these genes encode capsid proteins as well as genome replication and packaging proteins. AAV vectors typically have Rep and Cap replaced by target genes, resulting in a replication-deficient state where only the ITRs that enable replication and genome packaging remain. The AAV viral particle is also physicochemically stable. For these reasons, AAV has recently garnered attention for its utility as a gene delivery vector used in gene therapy for the treatment of congenital genetic diseases, as well as for the treatment of cancer or infections. The problem to be solved

[0007] In most cases, viral vectors, such as AAV-derived, adenovirus-derived, and lentivirus-derived vectors, are produced in host cells, such as mammalian cell lines. Typically, a method for producing recombinant viral vectors comprises the steps of introducing genetic elements for forming a viral vector into a host cell in the form of one or more nucleic acid constructs to generate a cell capable of producing a viral vector, and culturing said cell to express the elements for forming the viral vector. Among available cell lines, HEK293 cells or derivatives of HEK293 are widely used because they are well-characterized and highly sensitive to transfection. A significant advantage commonly possessed by mammalian cell lines, particularly those of human origin, is the ability to confer specific post-translational modifications (PTMs) to the vector capsid. These PTMs can affect in vivo stability, infectivity, and immunogenicity, and thus become important quality parameters.

[0008] AAV-based drugs are currently the most expensive drugs in the world, costing $1.2 million per patient for Glybera and $2 million for Zolgensma. The primary reason for the high price of AAV-based drugs is the current high manufacturing costs, which necessitates process optimization to enable cost-effective production. In the past, an increasing number of authors have proposed various approaches to process optimization in viral vector production. In addition to optimizing classical biotechnological parameters during production (i.e., upstream processes), the transfection process has been optimized to increase viral vector yield. Furthermore, downstream processes, which aim to isolate viral vectors from various impurities generated throughout the upstream production of viral vectors, are continuously being improved to achieve higher yields.

[0009] In most cases, since the majority of the generated viral vector remains inside the cell, the outer boundary or cell membrane must be broken down or destroyed. This release process is called cell lysis. To obtain maximum yield, the cell must be completely lysed so that virtually all DNA, RNA, and proteins within the cell become available. The field of cell lysis encompasses various methods, including mechanical approaches such as sonication and high-pressure homogenization, physical methods such as freeze-thaw, and chemical methods. However, each method has its own advantages and limitations. While mechanical cell lysis methods are effective for cell disruption, they can be difficult to scale up and may generate heat that leads to the denaturation of target molecules or the aggregation of viral vectors. Additionally, these methods often require specialized equipment and can be labor-intensive. The freeze-thaw method of cell lysis is relatively simple. However, this method relies on repetitive freeze-thaw cycles, which are time-consuming and may be impractical for large volumes; therefore, it cannot be easily scaled up and may not be suitable for large-scale production. Chemical cell lysis methods offer scalability and versatility as they can be formulated for different cell types and target molecules. However, in the field of viral vectors such as AAVs, chemical lysis compositions remain relatively inefficient, requiring multiple steps such as pre-cell separation and washing, long incubation times, and sequential nuclease treatment. Furthermore, current lysis compositions and protocols can result in high levels of co-extracted impurities, such as host cell nucleic acids, which makes downstream purification more difficult and reduces yield.Finally, many cell lysis reagents commonly used for AAV vector extraction contain 2-[4-(2,4,4-trimethylpentane-2-yl)phenoxy]ethanol or its derivatives, known as "Triton X-100," which are known biologically hazardous compounds listed on the REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) list and are therefore restricted or prohibited for use in the European Union. Furthermore, in addition to the aforementioned chemical lysis methods, combining chemical lysis with established mechanical techniques such as microfluidization or physical approaches such as freeze-thaw has been recognized as an effective cell lysis technique. However, while mechanical cell lysis methods are effective for cell disruption, they can result in product loss due to aggregation induced by shear stress. Moreover, these methods often require specialized equipment. On the other hand, combining chemical methods with freeze-thaw technology is also not an ideal solution. Although the freeze-thaw method for cell lysis is relatively simple, it relies on repetitive freeze-thaw cycles, which are time-consuming and may be impractical for large volumes; therefore, it cannot be easily scaled up and may not be suitable for large-scale production.

[0010] Consequently, there remains a significant need to improve viral vector production, particularly by enhancing the release of viral vectors from cell cultures. Specifically, there is a need to provide a simplified cell lysis workflow without compromising yield, or even while improving it. Furthermore, it is necessary to reduce the time required for cell lysis to enable the released viral vectors to be applied more rapidly to downstream purification.

[0011] Accordingly, the objective of the present invention is to improve cell lysis. Specifically, the objective is to increase the amount of released virus, that is, to increase the vector titer, e.g., the capsid and / or transfected viral vector titer. Furthermore, the objective may be to reduce and / or impurities released during cell lysis, or to improve the removal of impurities released along with the viral vector. Additionally, the objective may be to shorten the time required for lysis or to increase applicability to various sample types to simplify downstream processes. means of solving the problem

[0012] Summary of the Invention

[0013] The present invention addresses the aforementioned need by improving the release of a viral vector from a cell culture. The method comprises the step of providing a lysis reagent comprising a buffer having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M. This is followed by the step of contacting the cell culture with the lysis reagent to produce a lysis composition, and the step of incubating the lysis composition to release the viral vector from the cell culture, wherein, in step (b), it is not necessary to separate the cells of the cell culture from the surrounding liquid before contacting the cell culture with the lysis reagent. Since there is no need to separate the cells from the cell culture, the lysis reagent can be contacted directly without a cell separation step, thereby simplifying the cell lysis workflow. The lysis reagent, comprising buffer and salt of defined concentrations, allows for precise adjustment of the ionic strength of the lysis composition, ensuring that a large amount of the viral vector is released and maintained stably. Furthermore, the method can be flexibly applied to a wide range of samples and sample sizes, from cell culture media to cell pellets, thereby enabling broad applicability. In addition, the method according to the present invention enables the efficient release of a viral vector to maximize extraction while being mild to the viral vector to preserve its integrity and functionality, and achieves high functional / transduction potency by using carefully designed lysis reagents, for example, as disclosed herein. Finally, the presence of biological hazardous components or process steps is mitigated, ensuring the safety of workers and the environment. Compared to existing cell lysis reagent formulations and techniques, the cell lysis method, reagents, and kits according to the present disclosure have been carefully screened for optimal conditions.

[0014] According to a first embodiment, a method for releasing a viral vector from a cell culture is provided, said method comprising the following steps:

[0015] (a) a step of providing a dissolving reagent comprising a buffer solution having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M;

[0016] (b) a step of contacting the cell culture with the lysis reagent to produce a lysis composition; and

[0017] (c) a step of incubating the lysis composition so that the virus vector is released from the cell culture,

[0018] Here, in step (b), it is not necessary to separate the cells of the cell culture from the surrounding liquid before contacting the cell culture with the lysis reagent.

[0019] The method according to the first embodiment has the advantage of enabling the efficient release of a viral vector from a cell culture. Specifically, by providing a lysis reagent comprising a buffer having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M, the yield of capsid and functional viral vector titers could be improved within a short incubation time of less than 4 hours (see, for example, FIGS. 3 to 10). Furthermore, the ionic strength and the type of salt were carefully selected and screened to ensure high lysis efficiency and the stability of the viral vector. In addition, the method has the advantage that there is no need to separate cells from the cell culture before contacting the cell culture with the lysis reagent in step (b), that is, it can be applied to various samples including, for example, cell culture medium and other crude sample types (see, for example, FIGS. 11 to 14). By omitting the step of separating cells from the surrounding liquid, for example, through centrifugation, cell lysis is simplified, and there is the advantage of being able to apply directly to the cell culture in a culture vessel, for example, a bioreactor. At the same time, no biological hazardous ingredients or method steps are included, ensuring safety for workers and the environment (see FIGS. 15 to 17).

[0020] According to a second embodiment, a method for producing a virus vector is provided, said method comprising the following steps:

[0021] x.1 A step of providing a cell culture capable of producing a viral vector;

[0022] x.2 A step of producing a virus vector by culturing the above cell culture;

[0023] x.3 A step of releasing a virus vector from a cell culture according to a method according to a first embodiment; and

[0024] x.4 Optionally, a step of purifying the released virus vector.

[0025] According to a third embodiment, a cell lysis reagent for releasing a viral vector from a cell culture, preferably a cell culture medium, is provided, said cell lysis reagent is selected from one of the following:

[0026] i) Acidic dissolving reagents selected from the following:

[0027] I. 1x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0028] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer;

[0029] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0030] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0031] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0032] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0033] II. A 5x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0034] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer;

[0035] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0036] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0037] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0038] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0039] or

[0040] III. A 10x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0041] - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer;

[0042] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0043] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0044] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0045] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose;

[0046] ii) An alkaline dissolving reagent containing a detergent selected from the following:

[0047] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0048] - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0049] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0050] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0051] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0052] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0053] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0054] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0055] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0056] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0057] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0058] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0059] or

[0060] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0061] - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0062] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0063] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0064] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0065] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose;

[0066] or

[0067] iii) A detergent-free alkaline dissolving reagent selected from the following:

[0068] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0069] - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0070] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0071] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0072] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0073] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0074] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0075] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0076] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0077] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0078] or

[0079] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0080] - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0081] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0082] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0083] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose.

[0084] According to a fourth embodiment, a kit for releasing a viral vector from a cell culture, preferably a cell culture medium, is provided, wherein the kit comprises a container containing a cell lysis reagent according to a third embodiment of the present invention, and preferably one or more of the following:

[0085] (i) mammalian cells, preferably selected from HEK293 cells or derivatives of HEK293 cells;

[0086] (ii) one or more plasmids for the production of a viral vector;

[0087] (iii) transfection reagents; and / or

[0088] (iv) Cell culture medium.

[0089] Further aspects of the present invention are disclosed below. Other objects, features, advantages, and aspects of this application will become apparent to those skilled in the art from the following description and the appended claims. However, it should be understood that the following description, the appended claims, and specific embodiments represent preferred embodiments of this application but are provided merely for illustrative purposes. Brief explanation of the drawing

[0090] Some exemplary embodiments of the present disclosure will now be described with reference to the accompanying drawings. Figure 1 shows the schematic process flow of AAV vector production. Figure 2A shows the schematic process flow for cell lysis and capsid and functional potency quantification. Figure 2B shows an exemplary overview of the variables in the cell lysis study, including some but not all of the variables tested. FIG. 3 shows the functional titers of AAV2 determined after cell lysis and clarification by transduction analysis using the Incucyte® Live-Cell Analysis system. The N number designates the identification number of the AAV2 production and cell lysis conditions, where N1, N2, N5, N6, N9, and N10 relate to the acidic lysis reagents according to the present disclosure. The standard cell lysis reagents, "prior art cell lysis reagents" (N20 / 21 / 22), are highlighted in black. Error bars represent the standard deviation from the mean (n = 3). FIG. 4 shows the AAV2 capsid titers determined after cell lysis and clarification using Octet® AAVX biosensors. The N number designates the identification number of the AAV2 production and cell lysis conditions, where N1, N2, N5, N6, N9, and N10 relate to the acidic lysis reagents according to the present disclosure. The standard cell lysis reagents, "prior art cell lysis reagents (N20 / 21 / N22)," are highlighted in black. <LOQ는 정량 한계 미만의 값을 지칭한다. 오차 막대는 평균으로부터의 표준편차를 나타낸다(n = 3). Figure 5 shows a sterile filtration photograph of the crude lysate of HEK293 cells producing an AAV2 vector through a 0.22 μm CA Spin-X filter (Sigma Aldrich). The variables of the cell lysis conditions (pH, salt molar concentration, incubation time, and addition of detergent) are shown in the table, where N number refers to the identification number of the AAV2 production and cell lysis conditions, N2, N5, and N6 relate to the acidic lysis reagents according to the present disclosure, and N25 relates to a comparative condition having a pH of 8. The illustrated cell lysis setup was performed without a nuclease digestion step. Figure 6 is an SDS-PAGE analysis of sterile filtered crude lysates of HEK293 cells producing the AAV2 vector under reduction and denaturation conditions. Protein bands on the gel were visualized by Coomassie blue staining. Variables of cell lysis conditions (pH, salt molarity, incubation time, and addition of detergent) are shown in the table above the gel images, where N numbers refer to identification numbers for AAV2 production and cell lysis conditions, where N1, N5, and N9 relate to acidic lysis reagents according to the present disclosure, which were compared with pH 8 and pH 9 lysis reagents. M in lanes 1 and 13 is PageRuler TM This shows the unstained protein ladder (Thermo Fisher Scientific). FIG. 7 shows the functional titers of AAV2 determined after cell lysis and clarification by transduction analysis using the Incucyte® Live-Cell Analysis system. The N number designates the identification number of the AAV2 production and cell lysis conditions, where N7, N8, N5, N11, N12, N15, N16, N25, N27, N29, and N31 relate to alkaline lysis reagents containing detergent according to the present disclosure. The standard cell lysis reagents, "prior art cell lysis reagents" (N20 / 21 / 22), are highlighted in black. Error bars represent the standard deviation from the mean (n = 3). FIG. 8 shows the AAV2 capsid titers determined after cell lysis and clarification using Octet® AAVX biosensors. The N number designates the identification number of the AAV2 production and cell lysis conditions, where N7, N8, N11, N12, N15, N16, N25, N27, N29, and N31 relate to alkaline lysis reagents containing detergent according to the present disclosure. Standard cell lysis reagents, "prior art cell lysis reagents (N20 / 21 / N22)," are highlighted in black. <LOQ는 정량 한계 미만의 값을 지칭한다. 오차 막대는 평균으로부터의 표준편차를 나타낸다(n = 3). FIG. 9 shows the functional titers of AAV2 determined after cell lysis and clarification by transduction analysis using the Incucyte® Live-Cell Analysis system. The N number designates the identification number of the AAV2 production and cell lysis conditions, where N23, N24, N26, N28, and N30 relate to the detergent-free alkaline lysis reagents according to the present disclosure. The standard cell lysis reagents, "prior art cell lysis reagents" (N20 / 21 / 22), are highlighted in black. Error bars represent the standard deviation from the mean (n = 3). FIG. 10 shows the AAV2 capsid titers determined after cell lysis and clarification using Octet® AAVX biosensors. The N number designates the identification number of the AAV2 production and cell lysis conditions, where N23, N24, N26, N28, and N30 relate to the detergent-free alkaline lysis reagents according to the present disclosure. The standard cell lysis reagents, "prior art cell lysis reagents (N20 / 21 / N22)," are highlighted in black. <LOQ는 정량 한계 미만의 값을 지칭한다. 오차 막대는 평균으로부터의 표준편차를 나타낸다(n = 3). FIG. 11 shows the functional titers of AAV2 determined by transfection analysis using the Incucyte® Live-Cell Analysis system after cell lysis and clarification of the cell culture medium (Set A, see whole culture lysis). The N number designates the identification number of the AAV2 production and cell lysis conditions, where N70, N71, N72, and N73 relate to pH 2 acidic lysis reagents, N74, N75, N76, and N77 relate to pH 4 acidic lysis reagents, and N78, N79, N80, and N81 relate to pH 8 alkaline lysis reagents according to the present disclosure. As a reference lysis reagent, the "prior art cell lysis reagent" (N82) was applied, and CelLytic™ M (C1), CelLytic™ MT (C2; both from Sigma Aldrich), and M-PER (C3, Thermo Fisher Scientific) lysis reagents were also applied. Error bars represent the standard deviation from the mean (n = 3). Fig. 12 represents the AAV2 capsid titer determined using Octet® AAVX biosensors after cell lysis and clarification of the cell culture medium (see Set A, whole culture lysis). The N number designates the identification number of the cell lysis condition, where N70, N71, N72, and N73 relate to pH 2 acidic lysis reagents, N74, N75, N76, and N77 relate to pH 4 acidic lysis reagents, and N78, N79, N80, and N81 relate to pH 8 alkaline lysis reagents according to the present disclosure. As a reference lysis reagent, the "prior art cell lysis reagent (N82)" was applied, and CelLytic TM M(C1), CelLytic TMMT (C2; both Sigma Aldrich) and M-PER (C3, Thermo Fisher Scientific) dissolution reagents were also applied. Error bars represent the standard deviation from the mean (n = 3). Fig. 13 N represents the AAV2 functional titer determined by transfection analysis using the Incucyte® Live-Cell Analysis system after cell lysis and clarification of the cell pellet (see Set A, Cell Pellet Lysis). The N number designates the identification number of the AAV2 production and cell lysis conditions, where N86, N87, N88, and N89 relate to pH 2 acidic lysis reagents, N90, N91, N92, and N93 relate to pH 4 acidic lysis reagents, and N94, N95, N96, and N97 relate to pH 8 alkaline lysis reagents according to the present disclosure. The "prior art cell lysis reagent (N98)" was applied as the reference lysis reagent, and CelLytic TM M(C1), CelLytic TM MT (C2, both Sigma Aldrich) and M-PER (C3, Thermo Fisher Scientific) dissolution reagents were also applied. Error bars represent the standard deviation from the mean (n = 3). Fig. 14 represents the AAV2 capsid titer determined using Octet® AAVX biosensors after cell lysis and clarification of the cell pellet (see Set A, cell pellet lysis). The N number designates the identification number of the AAV2 production and cell lysis conditions, where N86, N87, N88, and N89 relate to pH 2 acidic lysis reagents, N90, N91, N92, and N93 relate to pH 4 acidic lysis reagents, and N94, N95, N96, and N97 relate to pH 8 alkaline lysis reagents according to the present disclosure. As a reference lysis reagent, the "prior art cell lysis reagent (N98)" was applied, and CelLytic TM M(C1), CelLytic TM MT (C2, both Sigma Aldrich) and M-PER (C3, Thermo Fisher Scientific) dissolution reagents were also applied. Error bars represent the standard deviation from the mean (n = 3). Figure 15 shows the functional titers of AAV2 determined by transfection analysis using the Incucyte® Live-Cell Analysis system after cell lysis and clarification of the cell culture medium (Set B, refer to whole culture lysis). The N number designates the identification number of the AAV2 production and cell lysis conditions, where N70A corresponds to the pH 2.75 acidic lysis reagent, N74A corresponds to the pH 4 acidic lysis reagent, and N78A corresponds to the pH 8 alkaline lysis reagent. The "prior art cell lysis reagent" (N82) was used as the reference lysis reagent, and the Triton X100-containing (TRT) lysis reagent was also used. Error bars represent the standard deviation from the mean (n = 3). Fig. 16 N represents the AAV2 capsid titer determined using Octet® AAVX biosensors after cell lysis and clarification of the cell culture medium (see Set B, whole culture lysis). The N number designates the identification number of the AAV2 production and cell lysis conditions, where N70A corresponds to the pH 2.75 acidic lysis reagent, N74A corresponds to the pH 4 acidic lysis reagent, and N78A corresponds to the pH 8 alkaline lysis reagent. The "prior art cell lysis reagent" (N82) was used as the reference lysis reagent, and the Triton X100-containing (TRT) lysis reagent was also used. Error bars represent the standard deviation from the mean (n = 3). Figure 17 shows the phase contrast confluence of adherent HEK293 cells transfected with sterile filtered crude AAV2 samples diluted to 1:10 to 1:320. Transfection analysis was performed using two types of AAV2 samples: samples lysed with a Triton X100-containing (TRT) lysis reagent and samples lysed with an alkaline lysis reagent (N78, LR2) containing Tween 20. Images were taken using an Incucyte® Live-Cell Analysis system. Figure 18 shows the total cell concentration and viability determined after lysis screening to compare different lysis approaches using HEK cell cultures for adenovirus vector production as a model. Samples S0 and S1 represent unlyzed cell cultures as a reference. Fig. 19 represents the adenovirus (AV) capsid titer determined using Octet® with an appropriate AV biosensor after cell lysis and centrifugation. Samples S0 and S1 represent unlyzed cell culture samples as a reference. Different lysis approaches were compared. Sample supernatants were measured directly immediately after centrifugation (without filtration) and also after 0.2 μm syringe filtration to compare whether the samples contained AV capsid aggregates (with filtration). Fig. 20 represents the relative amount of DNA impurities correlated with the amount of adenovirus (AV) capsid, determined after cell lysis and centrifugation. Samples S0 and S1 represent unlyzed cell culture samples as a reference. Different lysis approaches were compared. Sample supernatants were measured directly immediately after centrifugation (without filtration) and also after 0.2 μm syringe filtration to compare whether the samples contained impurity aggregates (with filtration). Fig. 21 represents the relative amount of host cell impurity (HCP) correlated with the amount of adenovirus (AV) capsid, determined after cell lysis and centrifugation. Samples S0 and S1 represent unlyzed cell culture samples as a reference. Different lysis approaches were compared. Sample supernatants were measured directly immediately after centrifugation (without filtration) and also after 0.2 μm syringe filtration to compare whether the samples contained impurity aggregates (with filtration). Specific details for implementing the invention

[0091] Detailed description of the invention

[0092] The following description is intended to deepen the understanding of the present disclosure and should be understood as supplementing and to be read together with the description of exemplary embodiments of the present disclosure provided in the above sections of this description. It should be understood that the present invention is not limited to the specific embodiments, methodologies, protocols, and reagents described herein, and that they may vary within the scope defined by the claims. Furthermore, it should be understood that the terms used herein are for the purpose of describing specific embodiments only and are not intended to limit the scope of the present invention as defined by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.

[0093] Specific elements of the present invention will be described in the following description. While these elements may be discussed in conjunction with specific embodiments, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The various examples, features, and specific embodiments described should not be construed as limiting the present invention to the explicitly described embodiments alone or to combinations of the explicitly described features alone. This description should be understood as disclosing and encompassing embodiments in which the explicitly described embodiments are combined with any number of disclosed and / or preferred elements. Furthermore, unless otherwise indicated by the context, any permutation and combination of all elements described in this application should be deemed to be disclosed by this description.

[0094] Method for releasing a viral vector from a cell culture

[0095] According to a first embodiment, a method for releasing a viral vector from a cell culture is provided, said method comprising the following steps:

[0096] (a) a step of providing a dissolving reagent comprising a buffer solution having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M;

[0097] (b) a step of contacting the cell culture with the lysis reagent to produce a lysis composition; and

[0098] (c) a step of incubating the lysis composition so that the virus vector is released from the cell culture,

[0099] Here, in step (b), it is not necessary to separate the cells of the cell culture from the surrounding liquid before contacting the cell culture with the lysis reagent.

[0100] The method according to the first embodiment has the advantage of enabling the efficient release of a viral vector from a cell culture. As demonstrated in the present disclosure, particularly in the examples, by providing a lysis reagent comprising a buffer having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M, the yield of the capsid and functional viral vector could be improved within a short incubation time of less than 4 hours (see, for example, FIGS. 3 to 10). Furthermore, the ionic strength and the type of salt were carefully selected and screened to ensure high lysis efficiency and the stability of the viral vector. Furthermore, the method has the advantage that there is no need to separate cells from the cell culture before contacting the cell culture with the lysis reagent in step (b), meaning it can be applied to various samples, including, for example, cell culture media and other crude sample types (see, for example, FIG. 11 to 14), as well as to different types of viral vectors, including AAV2, AAV8, and adenoviruses (see FIG. 1 to 16 and FIG. 19). By omitting the step of separating cells from the surrounding liquid, for example, through centrifugation, cell lysis is simplified, and there is the advantage that it can be applied directly to cell cultures within culture vessels, such as bioreactors. At the same time, safety for workers and the environment is ensured as no biological hazardous components or method steps are included (see FIG. 15 to 17).

[0101] Now, individual steps of the method according to the first aspect and preferred embodiments are described in detail.

[0102] Virus vector

[0103] A viral vector according to the present disclosure is any viral material (e.g., alone or in combination with additional viral or biochemical signals) suitable for delivering genetic material into a cell. In particular, as used herein, the terms “viral (vector),” “viral vector,” and “gene delivery vector” refer to a viral particle that functions as a means of delivering nucleic acids, comprising a nucleic acid molecule packaged within the viral particle. Viral vectors may be suitable for application in gene therapy, that is, they enable the use of nucleic acids to repair dysfunctional DNA sequences or to introduce compensatory changes that restore normal physiological functions of cells. Such gene delivery is also referred to as transduction. Generally, viral vectors for gene therapy are produced recombinantly to contain one or more target genes (also referred to as “transgenes”). Thus, according to a preferred embodiment, the viral vector is a recombinant viral vector. The target genes may be transduced into cells, e.g., patient cells, autologous cells, or allogeneic cells, which are in vivo ( in vivo ) or in a test tube ( in vitro ) or in vitro ( ex vivoThis may occur in ). Subsequently, one or more target genes are either directly available for protein expression within the cell as non-synthetic vectors that naturally degrade over time, or are incorporated into the cell's nuclear DNA. As used herein, "transplant gene" or "target gene" is a nucleic acid introduced into the genome, which includes, but is not limited to, a gene or nucleic acid having a sequence not normally present in a viral vector gene such as an AAV or adenovirus, a gene or nucleic acid present in a viral vector genome such as an AAV or adenovirus genome but not normally transcribed and translated ("expressed"), or any other gene or nucleic acid intended to be placed between viral vector repeat sequences such as the ITR sequence of an AAV. The transplant gene may include one or more transcriptional regulatory sequences, and any other nucleic acid that may be necessary for the optimal expression of the selected nucleic acid, such as introns. The transplanted gene may be only a few nucleotides in length, but preferably at least about 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800, 900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000, 2.100, 2.200, 2.300, 2.400, 2.500, 2.600, 2.700, 2.800, 2.900, 3.000, 3.100, 3.00, It may be 3.300, 3.400, 3.500, 3.600, 3.700, 3.800, 3.900, 4.000, 4.100, 4.200, 4.300, 4.400, 4.500, or 4.600 nucleotides (nt) in length. The transplanted gene may include a coding sequence or a non-coding sequence.

[0104] Importantly, and as demonstrated in the following examples, the method for releasing a virus vector according to the present disclosure is applicable to a wide range of virus vectors and is not limited to a specific type.

[0105] "Release a viral vector" refers to a process in which a viral vector produced by cells in a cell culture becomes accessible for additional processing steps, such as downstream purification and / or analysis. Typically, the viral vector resides primarily within the cells of the producing cell; therefore, the viral vector must be released to make it accessible for any subsequent processing steps. To achieve this, the cell membrane is typically degraded, meaning the cell undergoes lysis. Thus, a method for releasing a viral vector from a cell culture involves lysing the cells in the cell culture, and can likewise refer to, for example, a method of lysing the cells in the cell culture to release a viral vector.

[0106] Many viruses are known to be suitable as viral vectors for gene therapy, and this is known to those skilled in the art (see, e.g., Roldao et al., 2017, Comprehensive Biotechnology, vol. 1, pp. 633-656). Viral vectors may be selected from retroviruses such as lentiviruses, adenoviruses, herpes simplex, vaccinia, and adeno-associated viruses (AAVs). According to a preferred embodiment, the viral vector is a non-enveloped viral vector comprising, for example, an adeno-associated virus (AAV) or an adenovirus (Ad).

[0107] According to a preferred embodiment, the viral vector is selected from an adeno-associated virus (AAV) or an adenovirus (Ad), most preferably the viral vector is an AAV. As demonstrated in the following examples, the method according to the present disclosure improves the release of AAV and adenovirus, particularly by increasing genomic titers and transduction titers (see FIGS. 1 to 21).

[0108] According to a preferred embodiment, the viral vector is primarily present inside the cell. However, a portion of the viral vector may also be present outside the cell, for example, due to cell degradation or lysis during the production process of the viral vector. It is also within the scope of the present invention to apply the method according to the present disclosure to release a viral vector present outside the cell, where only a portion is present inside the cell. For example, some serotypes, such as AAV8, are known to be efficiently released into the surrounding culture medium by the cell, and thus a portion of the produced viral vector is not present inside the cell.

[0109] As used herein, the term "adeno-associated virus (AAV)" refers to, but is not limited to, AAV type 1 (e.g., AAV of serotype 1, also referred to as AAV1), AAV type 2 (e.g., AAV2), AAV type 3 (e.g., AAV3 including types 3A and 3B, AAV3A and AAV3B), AAV type 4 (e.g., AAV4), AAV type 5 (e.g., AAV5), AAV type 6 (e.g., AAV6), AAV type 7 (e.g., AAV7), AAV type 8 (e.g., AAV8), AAV type 9 (e.g., AAV9), AAV type 10 (e.g., AAV10), AAV type 11 (e.g., AAV11), AAV type 12 (e.g., AAV12), AAV type 13 (e.g., AAV13), AAV Includes rh32.33 type (e.g., AAVrh32.33), AAV rh8 type (e.g., AAVrh8), AAV rhlO type (e.g., AAVrhlO), AAV rh74 type (e.g., AAVrh74), AAV hu.68 type (e.g., AAVhu.68), avian AAV (e.g., AAAV), cattle AAV (e.g., BAAV), dog AAV, horse AAV, sheep AAV, snake AAV, bearded dragon AAV, AAV2i8, AAV2g9, AAV-LK03, AAV7m8, AAV Anc80, AAV PHP.B, and any other AAV currently known or to be discovered in the future.

[0110] cell culture

[0111] According to the disclosed method for releasing a viral vector, the viral vector is released from a cell culture, wherein in step (b), there is no need to separate the cells of the cell culture from the surrounding liquid before contacting the cell culture with the lysis reagent. Since there is no need to separate the cells from the surrounding liquid before contacting the cell culture with the lysis reagent in step (b), there is no need for additional process steps. In other words, the cells do not need to undergo any kind of separation step, such as centrifugation or sedimentation, before contacting the lysis reagent. As a result, the method of the present disclosure simplifies cell lysis and expands applicability by performing cell lysis directly, for example, in a bioreactor.

[0112] The “cell culture” according to the present disclosure comprises cells and surrounding liquid, as well as any product produced by a viral vector, such as AAV or adenovirus. Typically, the cell culture is a suspension of cells comprising cells, preferably HEK293 cells or their derivatives, surrounding liquid such as a cell culture medium, and a product produced by said cells (in this case, a viral vector). Cell culture media suitable for cell culture are known in the art and are not limited to the present disclosure. Examples of cell culture media suitable for culturing HEK293 cells can be found in the following examples. Cell culture media may be HEK ViP NB and HEK TF (Sartorius Xell GmbH), and DMEM (Pan-Biotech). In addition to cells and surrounding liquid, the cell culture may contain additional compounds, such as residues of transfection reagents, compounds that promote viral vector production, etc.

[0113] According to a preferred embodiment, the cell culture is a cell broth or a cell pellet, preferably a cell broth. The cell broth comprises cells producing a viral vector, a surrounding culture medium, and, if already produced, the viral vector. This may be referred to as the "whole (cell) culture," "cell culture fluid," or "cell culture suspension." As demonstrated in the examples, the method according to the present disclosure is suitable for cell broths and other crude samples (see FIGS. 11, 12, 15 and FIGS. 16 through 21), as well as for purified or processed samples such as cell pellets (see FIGS. 13 and 14). This demonstrates the broad and advantageous applicability of the method according to the present disclosure.

[0114] According to a preferred embodiment, the cell culture does not undergo sonication, high-pressure homogenization, or freeze-thaw. This embodiment is advantageous because such methods may be difficult to scale up and may generate heat that can lead to denaturation of target molecules or aggregation of viral vectors. Furthermore, such methods often require specialized equipment, for example, for sonication and high-pressure homogenization, can be labor-intensive, and may cause contamination by released viruses. Moreover, freeze-thaw methods rely on repeated freeze-thaw cycles, which are time-consuming and impractical for large volumes, making them difficult to scale up and unsuitable for large-scale production. On the other hand, the method of the present disclosure provides scalability and versatility because the lysis reagent can be formulated to suit different cell types and viral vectors.

[0115] According to a preferred embodiment, the cell culture does not undergo centrifugation, cell pelleting, or exchange of the liquid surrounding the cells in the cell culture prior to steps (a), (b), and (c). Avoiding centrifugation or sedimentation simplifies the process and avoids labor-intensive and potentially contaminating steps, for example, when removing the supernatant.

[0116] According to a preferred embodiment, the cell culture comprises mammalian cells. The mammalian cells are cells of mammalian origin. However, the cells do not need to be identical to cells obtained from mammals and may be modified, manipulated, or naturally or artificially altered. For example, the mammalian cells may be cells of mammalian origin, but may include one or more genetic modifications to proliferate them repeatedly and, if possible, indefinitely. The term "mammalian cells" may be used interchangeably with "mammalian cells" and encompasses both singular and plural forms. The mammalian cells are preferably mammalian cell lines. According to a preferred embodiment, the mammalian cells are human-derived cell lines, which have the advantage of having the ability to provide post-translational modifications suitable for treatment in humans. This means that the produced viral vector has post-translational modifications similar to those that occur when a natural virus infects a human cell to produce a virus.

[0117] The above mammalian cells may be selected from a group consisting of sub-cell lines such as HeLa, human embryonic kidney 293 (HEK293), BSC-1, SW480, baby hamster kidney (BHK), BHK-21, Vero E6, U2OS, A549, HT1080, CAD, P19, NIH 3T3, L929, N2a, Chinese hamster ovary (CHO), MCF-7, Y79, SO-Rb50, Hep G2, DUKX-X11, J558L, HuH-7, MDCK, or HepG2 cells or derivatives thereof, for example, in the case of HEK293, HEK293-T, HEK293-F, HEK293-FT, etc. According to a preferred embodiment, the mammalian cell is selected from the group consisting of HEK293, A549, BSC-1, SW480, baby hamster kidney (BHK), Vero E6, and MDCK cells or derivatives thereof. According to a more preferred embodiment, the mammalian cell is selected from HEK293 cells or derivatives of HEK293 cells. HEK293 is particularly advantageous because it is well-characterized, widely used, and highly sensitive to transfection. HEK293 cells were established by transfecting human embryonic kidney cells with cleaved adenovirus type 5 DNA. Accordingly, the mammalian cell may be a HEK293 cell or a derivative of the HEK293 cell, and may be selected from, for example, HEK293, HEK293T, HEK293T / 17, ANJOU 65, HEK293H, HEK293E, HEK293-6E, HEKEBNA1-6E, HEK293F, HEK293FT, HEK293Flp-IN T-REx, HEK293FTM, HEK293S, HEK293SG, HEK293SGGD, HEK293MSR, HEK293A, or any modified variant thereof.Derivatives of HEK293 cells may also include HEK293 cells adapted to suspension culture and / or specific types of cell culture media.

[0118] According to a preferred embodiment, the cell culture comprises cells that can be cultured in a suspension state. For example, HEK293 cells or derivatives of HEK293 cells are adapted for suspension culture. This is particularly advantageous as it allows for obtaining a larger number of cells compared to adherent cells. It is also possible to use originally adherent cells, for example, adherent HEK293 cells, and then adapt them for suspension culture and subsequently modify them to be configured to produce a viral vector (e.g., by transient transfection or genome editing).

[0119] According to a preferred embodiment, the mammalian cell is modified to be configured to produce a viral vector, preferably an AAV. According to one embodiment, the mammalian cell is modified to be configured to produce a viral vector (preferably prior to step (a)). In another embodiment, one may start directly with the mammalian cell without any active modification step by purchasing a mammalian cell capable of producing the desired viral vector, for example, a so-called packaging cell or stable cell containing all the genetic elements necessary to express the viral vector, excluding typically the target gene(s). In some embodiments, the mammalian cell to be applied may be one that is capable of expressing one or more genes necessary to produce the viral vector from the outset, for example, HEK293 cells are known to express E1A and E1B necessary to produce AAV.

[0120] According to a preferred embodiment, the mammalian cell is modified by transiently transfecting the mammalian cell with one or more plasmids for viral vector production that enable transient viral vector production. The transiently transfected mammalian cell essentially enables a single run of viral vector production, and thus transfection must be performed for each production run. According to an alternative preferred embodiment, the mammalian cell is modified by genome editing the mammalian cell with one or more nucleic acid molecules for viral vector production that enable stable viral vector production. Stable integration allows a stock of modified mammalian cells, e.g., a cell bank or master cell bank, to be used multiple times without the need to genetically modify the mammalian cell prior to each production run (compared to transient transfection). This has the advantage of simplifying and making the process more efficient by allowing an established process to be repeated multiple times without the need to perform transient transfection beforehand. On the other hand, transient transfection is more flexible because it allows different sets of genetic elements to be transfected into the cell for each run without complex genome editing of the mammalian cell prior to transfection. Both of these methods of modifying mammalian cells to produce viral vectors are applicable within the framework of the methods according to the present disclosure and are not limited in any way. In fact, combining transient transfection and stable integration is also within the scope of the present disclosure, for example, by providing some genetic elements stably integrated and others through transient transfection. For example, the transplant gene cassette may be provided by transient transfection, while the remaining genetic elements may be stably integrated.

[0121] According to a preferred embodiment, the one or more plasmids or the one or more nucleic acid molecules for producing a viral vector encode at least a portion of an adenovirus (Ad) or at least a portion of an adeno-associated virus (AAV). In some cases, for example, where some of the genetic elements are already present in mammalian cells, it is not necessary for all genetic elements naturally possessed by the virus to be present in the one or more plasmids or the one or more nucleic acid molecules for producing a viral vector. For example, HEK293 cells, commonly used to produce viral vectors, were originally established by transfecting primary human embryonic kidney cells with cleaved adenovirus 5 DNA, and HEK293 cells were shown to stably express adenovirus E1A and E1B-55k proteins because a 4 kbp adenovirus DNA fragment is incorporated on chromosome 19. Therefore, E1A and E1B do not need to be included in the genetic design for modifying these mammalian cells (but may be included). Additionally, for gene therapy, the produced viral vector generally contains one or more genes to be delivered to a patient or other cells. One or more of these genes may be referred to as "target gene(s)." These typically replace the viral vector production machinery packaged within a plasmid, because replicating the viral vector in vivo, i.e., in a potential patient, is generally undesirable. Therefore, rather than the natural complete viral vector genetic elements being delivered, only the genetic elements for producing the viral vector, including the target gene(s), may be delivered. In some embodiments, the target gene is a therapeutic nucleic acid, such as therapeutic DNA or RNA. In other embodiments, the target gene includes a reporter gene. In a preferred embodiment, the reporter gene may be detected by an antibody-based assay.In a further preferred embodiment, the reporter gene is a fluorescent molecule. Exemplary fluorescent molecules suitable as reporter genes are GFP, eGFP, mGFP, eYFP, citrine, eCFP, mCFP, cerulean, dtTomato, and any variants thereof. In some embodiments, the reporter gene is beta-galactosidase, luciferase, or glutathione S-transferase, or any variant thereof. In certain embodiments, the target gene is suitable for a screening assay or marker, such as a fluorescent protein like green fluorescent protein (GFP) or a derivative thereof, used to visualize the transduction of a viral vector.

[0122] According to a preferred embodiment for producing AAV, the one or more plasmids or the one or more nucleic acid molecules for producing a viral vector encode one or more of the group comprising Rep78, Rep68, Rep52, Rep40, VP1, VP2, VP3, ITR, AAP, MAAP, X gene, VA RNA, E4orf6, and E2A, preferably all of the foregoing, to produce AAV. According to another embodiment, the one or more plasmids or the one or more nucleic acid molecules for producing a viral vector encode one or more of the group comprising Rep78, Rep68, Rep52, Rep40, VP1, VP2, VP3, ITR, AAP, MAAP, X gene, VA RNA, E4orf6, E1A, E1B, and E2A, preferably all of the foregoing, to produce AAV. In either of these embodiments, the mammalian cell may already encode one or more of the genetic elements for producing AAV. For example, E1A and E1B may already be produced by mammalian cells, e.g., HEK293, where a plasmid or nucleic acid molecule may support intracellular expression by additional copies of E1A or E1B, or intracellular expression may be considered sufficient. The encoded gene may be provided on a single or multiple plasmids or a single or multiple nucleic acid molecules. According to one embodiment, more than one plasmid is provided to produce AAV. For example, two, three, four, five, six, seven, eight, nine, or ten plasmids may be provided.

[0123] Dissolving reagent

[0124] According to method step (a), the method comprises the step of providing a dissolving reagent comprising a buffer having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M. The present disclosure provides various dissolving reagents as exemplified in the Examples section. However, generally, all dissolving reagents according to the present disclosure comprise at least a buffer having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M. Accordingly, the method according to the present disclosure comprises the step of providing a dissolving reagent comprising a buffer having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M. It has been found that a combination of buffer and salt of these concentrations allows for precise tuning of ionic strength, thereby enabling the efficient release of the viral vector without significant aggregation and consequently obtaining a high viral vector titer (see FIGS. 3 to 16 and FIG. 19). The salt according to the present disclosure differs from the buffer solution in that it cannot be the same or identical compound as the buffer solution.

[0125] Preferably, the lysis reagent is provided in a liquid form, e.g., as a solution or suspension. This is typically easier to handle and easier to perform the contact step. Additionally, this may be more precise than adding the reagent in a solid form. According to another embodiment, the lysis reagent is provided in a solid form, e.g., as a powder. Such a solid lysis reagent may be present in a container, wherein the cell culture is added in the contact step (b) according to the present disclosure. The specific form of the lysis reagent does not limit the scope of the present disclosure.

[0126] The term "lysis reagent" may be used interchangeably with the term "cell lysis reagent" herein.

[0127] According to a preferred embodiment, the dissolving reagent comprises a buffer solution having a concentration selected from the following range:

[0128] i) For 1x dissolving reagent, 0.05 M to 1 M;

[0129] ii) 0.3 M to 1.5 M for 5x dissolution reagent; or

[0130] iii) Preferably, for a 10x dissolving reagent, 1 M to 3 M.

[0131] These concentrations have been found to be particularly advantageous for releasing viral vectors. When applied to cell culture media, high concentrations of lysis reagent, such as 5x or 10x, preferably 10x, are particularly advantageous because they reduce the volume of lysis reagent that must be added to the cell culture. As a result, if the culture vessel, for example, a bioreactor, has sufficient (head) space to be filled with lysis reagent, it may be possible to add the lysis reagent directly to the culture vessel.

[0132] Throughout the present disclosure, the concentration of a compound relates to the x-fold lysis reagent. This specifically refers to the ratio of cell culture to lysis reagent. For example, 1x lysis reagent is typically added to a cell culture that essentially contains no or very little ambient liquid, such as a cell pellet or a precipitated cell culture without supernatant. 5x lysis reagent typically involves mixing 4 parts of cell culture with 1 part of lysis reagent, for example, mixing 4 mL of cell culture with 1 mL of lysis reagent. 10x lysis reagent typically involves mixing 9 parts of cell culture with 1 part of lysis reagent, for example, mixing 9 mL of cell culture with 1 mL of lysis reagent.

[0133] According to a preferred embodiment, the salt is selected from potassium chloride and sodium chloride. As demonstrated in the examples, these salts are particularly useful for adjusting ionic strength to allow for the release of large amounts of viral vectors. Furthermore, as commonly used buffer salts, they are not dangerous and are non-toxic.

[0134] According to a preferred embodiment, the buffer concentration is selected from the following range:

[0135] i) For 1x dissolving reagent, 0.05 M to 1 M;

[0136] ii) 0.3 M to 1.5 M for 5x dissolution reagent; or

[0137] iii) Preferably, for the 10x dissolving reagent, 0.8 M to 5 M or 1 M to 3 M.

[0138] These buffer concentrations have been found to be particularly advantageous for releasing viral vectors. When applied to cell culture media, high concentrations of lysis reagent, such as 5x or 10x, preferably 10x, are particularly advantageous because they reduce the volume of lysis reagent that must be added to the cell culture. As a result, if the culture vessel, for example, a bioreactor, has sufficient (head) space to be filled with lysis reagent, it may be possible to add the lysis reagent directly to the culture vessel. As demonstrated in the examples, the concentrations of the buffer and salt together allow for the careful selection of appropriate concentrations to achieve an ionic strength that maximizes the amount of viral vector released while keeping viral vector aggregation low, thereby enabling improved release of the viral vector.

[0139] According to a preferred embodiment, the dissolving reagent does not contain substances from the group of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated. According to a preferred embodiment, the dissolving reagent does not contain Triton X-100. Avoiding these compounds has the advantage that biologically hazardous compounds are not added.

[0140] divalent cation

[0141] According to a preferred embodiment, the dissolving reagent is a divalent cation, preferably Mg 2+ , Ca 2+ , Ba 2+ , Cu 2+ , Fe 2+ , Zn 2+ , Mn 2+ , Ni 2+ or a combination thereof, more preferably Mg 2+ , Cu 2+ , Zn 2+ , Mn 2+ , Ni 2+ or a combination thereof, most preferably Mg 2+ It additionally includes. Divalent cations are particularly advantageous for cell lysis involving nucleases, for example, because they enable or enhance nuclease activity as cofactors of such nucleases. Furthermore, Mg 2+ It is believed that the presence of divalent cations such as [such as] can stabilize viral vectors such as AAV. In some cases, divalent cations may not be necessary when a nuclease is not applied, particularly in the case of the acidic lysis reagent described below, for example.

[0142] According to a preferred embodiment, the divalent cation in the dissolution reagent has a concentration of 0.1 mM to 100 mM, preferably selected from the following range:

[0143] i) For the 1x dissolution reagent, 0.5 mM to 5 mM;

[0144] ii) For the 5x lysis reagent, 5 mM to 15 mM; or

[0145] iii) Preferably, for the 10x dissolution reagent, 15 mM to 50 mM.

[0146] It was found that such divalent cation concentrations are advantageous for releasing viral vectors.

[0147] cryoprotectant

[0148] According to a preferred embodiment, the lysis reagent further comprises a cryoprotectant, preferably a sugar, more preferably sucrose, trehalose, or mannitol, most preferably sucrose. The capsid and functional viral vector titer, i.e., the release of the viral vector, are not affected by the presence of the cryoprotectant, and thus the compound is not essential for release. However, when the cryoprotectant is optionally added to the lysis reagent according to the present disclosure, it provides the advantage of improving the shelf life and freezing of the viral vector-containing composition after lysis and / or purification. However, the cryoprotectant does not need to be present during cell lysis and may be added later, for example, after step (c) of the method according to the present disclosure. It may be advantageous to include the cryoprotectant in the lysis reagent to avoid a subsequent addition step, that is, a lysis reagent containing the cryoprotectant simplifies the lysis process because there is no need to add the cryoprotectant during or after lysis.

[0149] According to a preferred embodiment, the cryoprotectant in the dissolving reagent has a concentration of 1% (w / v) to 70% (w / v), preferably a concentration selected from the following ranges:

[0150] i) For 1x dissolution reagent, 1% (w / v) to 10% (w / v);

[0151] ii) For 5x dissolution reagent, 10% (v / v) to 35% (w / v); or

[0152] iii) For 10x dissolution reagent, 20% (w / v) to 60% (w / v).

[0153] It has been found that such cryoprotectant concentrations are advantageous for the stability of viral vectors during cryopreservation.

[0154] acidic dissolving reagent

[0155] According to a preferred embodiment, the lysis reagent is an acidic lysis reagent, preferably having a pH of less than 6.0, preferably less than 5.0, and most preferably less than 4.5. According to a particularly preferred embodiment, the acidic lysis reagent has a pH of less than 6.0, preferably less than 5.0, and most preferably less than 4.5. As demonstrated in the examples (see FIGS. 3, 4, 11 to 16), the acidic lysis reagent efficiently releases the viral vector from the cell culture compared to lysis reagents of the latest technology, resulting in a high AAV yield. Furthermore, the acidic lysis reagent enables the efficient removal of host cell-associated impurities by facilitating the efficient precipitation of such impurities (see FIG. 6). Moreover, purity indicates high stability in the lysis composition, and the acidic lysis reagent minimizes AAV vector aggregation. Finally, the acidic lysis reagent is highly efficient in that vector extraction can be achieved within 30 to 120 minutes, which is significantly shorter than conventional lysis protocols.

[0156] According to a preferred embodiment, the acidic dissolving reagent has a pH selected from the range of 1.8 to 6.0 or 2.0 to 5.5, preferably 2.75 to 5.0. This pH range enables efficient release of the viral vector. According to a specific embodiment, the pH is selected from the range of 1.8 to 6.0, 1.9 to 5.9, 2.0 to 5.8, 2.0 to 5.7, 2.0 to 5.6, 2.0 to 5.5, 2.1 to 5.4, 2.2 to 5.3, 2.3 to 5.2, 2.4 to 5.1, and 2.5 to 5.0. These pH values ​​include, for example, a pH of about 2.0 (including a value of + / - 10%) or a pH of about 4.0 (including a value of + / - 10%).

[0157] According to a preferred embodiment, the acidic dissolving reagent comprises a buffer suitable for buffering the acidic dissolving reagent at an acidic pH, preferably 1.0 to 7.0, more preferably 2.0 to 6.0. A buffer that efficiently buffers the acidic dissolving reagent (and subsequently the dissolving composition) at an indicated acidic pH is particularly suitable for the method of the present disclosure because it maintains the pH relatively stable at an acidic pH.

[0158] According to a preferred embodiment, the acidic dissolution reagent comprises an acetate buffer, a hydrochloric acid-potassium chloride buffer (HCl-KCl), a glycine buffer, a citrate buffer, a citrate-phosphate buffer, a phosphate buffer, a glycyl-glycine buffer, a sodium formate buffer, a succinate buffer, a pyridine buffer, a 2-(N-morpholino)ethanesulfonic acid (MES) buffer, a 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol (BIS-TRIS) buffer, or a combination thereof, preferably a buffer selected from an acetate buffer or a glycine buffer. These buffer compounds have been found to be suitable for acidic dissolution reagents because they efficiently buffer the dissolution reagent and possibly the dissolution composition at an acidic pH.

[0159] In one embodiment, the pH of the acidic dissolving reagent is selected from the range of 2.0 to 6.0, and the following buffer may be selected:

[0160] i) Hydrochloric acid-potassium chloride buffer (HCl-KCl); pH range 1.0 to 2.2,

[0161] ii) Glycine-HCl buffer; pH range 2.0 to 3.6,

[0162] iii) Citrate buffer; pH range 3.0 to 6.2,

[0163] iv) Acetate buffer; pH range 3.6 to 5.6, or

[0164] v) Citrate-phosphate buffer; pH range 2.6 to 7.0.

[0165] According to a preferred embodiment, in step (b) of the method according to the present disclosure, the dissolved composition is:

[0166] i) Having a pH of less than 5.0, preferably less than 4.5;

[0167] ii) It has a pH selected from the range of 2.5 to 5.0, preferably 3.5 to 4.5, and

[0168] However, the above dissolving reagent is subject to the condition that it is an acidic dissolving reagent.

[0169] A soluble composition having the indicated pH (see exemplary soluble composition in Table 5) was found to be efficient in releasing viral vectors and additionally reduce host cell-associated impurities (see Fig. 6).

[0170] According to a preferred embodiment, nuclease is not added, particularly with respect to acidic dissolving reagents. Not requiring nuclease is advantageous because nuclease is associated with high costs and additional process steps, such as the addition and incubation of nuclease at specific temperatures.

[0171] According to a preferred embodiment, the released viral vector is purified after step (c) preferably by at least deep filtration, centrifugation, and / or sterile filtration, wherein the released viral vector contains at least 20% less, preferably 25% less, more preferably 30% less or 35% less host cell-derived DNA impurities compared to a method in which the lysis reagent is a neutral or alkaline lysis reagent rather than an acidic lysis reagent. Due to the low pH of the reagent, possibly due to the precipitation of host cell proteins and nucleic acids, the cell lysate exhibits reduced viscosity. This enables efficient filtration without requiring additional nuclease digestion (see Fig. 5 for settings N2, N5, and N6).

[0172] According to a preferred embodiment, the released viral vector is purified after step (c) preferably by at least deep filtration, centrifugation, and / or sterile filtration, wherein the released viral vector contains at least 25% less, preferably 50% less, more preferably 60% less, or 70% less host cell-derived protein impurities compared to a method in which the lysis reagent is a neutral or alkaline lysis reagent rather than an acidic lysis reagent. Due to the low pH of the reagent, possibly due to the precipitation of host cell proteins and nucleic acids, the cell lysate exhibits reduced viscosity. This enables efficient filtration without requiring additional nuclease digestion (see Fig. 5 for settings N2, N5, and N6). Additionally, host cell-associated protein impurities are significantly reduced (see Fig. 6).

[0173] Exemplary acidic dissolving reagents can be found in Table 1.

[0174] alkaline dissolving reagent

[0175] According to a preferred embodiment, the dissolution reagent is an alkaline dissolution reagent, preferably with a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, e.g., 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, or greater than 8.5. According to a particularly preferred embodiment, the alkaline dissolution reagent has a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, e.g., 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, or greater than 8.5. Such alkaline pH values ​​have been found to be advantageous for the method according to the present invention for maximizing yield. Specifically, the inventors have found that the alkaline dissolution reagent improves the extractability of the intracellular AAV vector (see Examples 2 and 3, FIG. 7 to 10). By improving AAV vector extraction efficiency using the developed cell lysis reagent, it is possible to significantly reduce the manufacturing costs of AAV-based drugs. The enhanced extraction efficiency, demonstrated by AAV2 transduction assay results, leads to a higher yield of active AAV vectors. Higher AAV vector yields mean that more drugs can be obtained from the same production process, thereby increasing overall productivity and reducing the cost per unit. Furthermore, the alkaline lysis reagent disclosed herein enables shorter cell lysis and extraction times. These time-saving aspects can lead to significant cost reductions by decreasing the total time required for the production cycle.

[0176] According to a preferred embodiment, the alkaline dissolving reagent has a pH selected from the range of 7.2 to 10, preferably 7.5 to 9.5. According to a specific embodiment, the alkaline dissolving reagent has a pH selected from the range of 7.2 to 10, 7.3 to 9.9, 7.3 to 9.8, 7.4 to 9.7, 7.4 to 9.6, preferably 7.5 to 9.5. These ranges are advantageous for achieving efficient release of the viral vector.

[0177] According to a preferred embodiment, the alkaline dissolving reagent comprises a buffer solution suitable for buffering the alkaline dissolving reagent at an alkaline pH, preferably one selected from the range of 7.2 to 9.5. A buffer solution that efficiently buffers the alkaline dissolving reagent (and subsequently the dissolving composition) at an indicated acidic pH is particularly suitable for the method of the present disclosure because it maintains the pH relatively stably at an alkaline pH.

[0178] According to a preferred embodiment, the alkaline dissolving reagent comprises a buffer selected from tris(hydroxymethyl)-aminomethane (TRIS) buffer, 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer, phosphate buffer, glycine-sodium hydroxide buffer, 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) buffer, TES buffer, DIPSO buffer, TAPSO buffer, triethanolamine buffer, HEPPSO buffer, POPSO buffer, TRICINE buffer, HEPPS buffer, EPPS buffer, BICIN buffer, TAPS buffer, AMPSO buffer, taurine buffer, CHES buffer, AMP buffer, CAPSO buffer, or a combination thereof, preferably a buffer selected from TRIS buffer or BTP buffer. These buffer compounds have been found to be suitable for alkaline dissolving reagents because they efficiently buffer dissolving reagents and possibly dissolving compositions at alkaline pH.

[0179] In one embodiment, the pH of the alkaline dissolving reagent is selected from the range of 7.5 to 9.5, and the following buffer may be selected:

[0180] i) TRIS buffer; pH range 7.5 to 9.0,

[0181] ii) BTP buffer, pH range 6.3 to 9.5,

[0182] iii) Phosphate buffer; pH range 5.8 to 8.0, or

[0183] iv) Glycine-sodium hydroxide, pH 8.6 to 10.6.

[0184] According to a preferred embodiment, in step (b), the dissolved composition has the following pH:

[0185] i) Greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0; and / or

[0186] ii) pH selected from the range of 7.2 to 10.0, preferably 7.5 to 9.5,

[0187] However, the above dissolving reagent is subject to the condition that it is an alkaline dissolving reagent.

[0188] A dissolution composition having the indicated pH (see exemplary dissolution composition in Table 5) was found to be efficient in releasing a viral vector (see Figures 7 to 10, 19).

[0189] According to a preferred embodiment, the method further comprises the step of providing a nuclease to be added to the lysis reagent, the cell culture and / or the cell lysis composition, preferably the cell culture and / or the cell lysis composition. In one embodiment, the nuclease is added to the lysis composition after step (b) (see also Examples 2 and 3), but likewise the nuclease may be added to the lysis reagent before step (b). Within the scope of the present disclosure, the addition of the nuclease is typically used to achieve three purposes: (i) reducing nucleic acid contamination, (ii) reducing the viscosity of the cell lysate, and (iii) mitigating AAV vector aggregation caused by the binding of the nucleic acid to the surface of the AAV vector particles. According to a preferred embodiment, the nuclease is salt-tolerant. Salt-tolerant nucleases enable use in compositions of higher ionic strength, such as those that may be present in the lysis composition and / or lysis reagent according to the present disclosure. Examples of nucleases or salt-tolerant nucleases are well known to those skilled in the art, and the specific enzymes used do not limit the scope of this disclosure. Examples of applicable salt-tolerant nucleases are M-SAN HQ and SAN-HQ (ArcticZymes). Typical suitability conditions for nucleases such as "San HQ 2.0 (ArcticZymes)" are as follows:

[0190] i) Temperature: 7 - 38℃, overnight at 4℃, optimal: 30 - 38 ℃

[0191] ii) Salt concentration (NaCl / KCl): 100 - 900 mM, Optimum: 400 - 650 mM,

[0192] iii) Mg 2+ : >1 mM is beneficial for activity, optimal 5 - 50 mM,

[0193] iv) pH: 7.3 - 9.2, optimal 8.2 - 8.8.

[0194] Exemplary alkaline dissolving reagents can be found in Tables 2 and 3.

[0195] cleanser

[0196] The lysis reagent according to the present disclosure may contain or may not contain a detergent. In particular, it has been found that an acidic lysis reagent containing a detergent as disclosed herein effectively lyses cells and thereby releases a viral vector from the cell culture (see, e.g., Example 1, Table 1). Accordingly, according to a particularly preferred embodiment, the acidic lysis reagent further comprises a detergent. On the other hand, an alkaline lysis reagent can be flexibly applied with or without a detergent and still exhibits excellent release of the viral vector (see Examples 2 and 3, Tables 2 and 3). Accordingly, the alkaline lysis reagent may contain or may not contain a detergent.

[0197] According to a preferred embodiment, the dissolving reagent comprises a detergent, preferably a nonionic detergent, more preferably a nonionic detergent that is not classified as toxic and / or harmful to the environment, and / or a nonionic detergent that is toxic and / or harmful to the environment. Preferably, the detergent according to the present disclosure is safe for humans and the environment, thus having the advantage of eliminating potential biological hazards associated with the use of detergents such as, for example, Triton-X100 or similar detergents. While this is advantageous, the dissolving reagent may also include such detergents if desired. According to a preferred embodiment, the detergent is selected from one or more of Tween, Triton, Nonidet, Igepal, or Tergitol, preferably from Tween. Any nonionic detergent may be used, but examples of nonionic detergents include those of the Tween series (Tween-20, Tween-40, Tween-60, Tween-80, etc.), Triton series (X-100, X-114, XL-80N, etc.), Tergitol (XD, TMN-6, etc.), and Nonidet or Igepal (NP-40, etc.). Nonionic surfactants include, but are not limited to, alkyl glucosides, particularly polysorbates such as polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), and polysorbate 80 (Tween 80), and corresponding nonionic detergents of the Brij series and polyoxyethylene alkyl ethers such as Triton X-100, Nonidet P40, NP-40. Additional detergents useful in methods for dissolving or decomposing a sample are also well known in the prior art and therefore do not need to be described in detail here. Additionally, mixtures of detergents may be used.

[0198] According to a preferred embodiment, the detergent is an alkyl glucoside, preferably a polysorbate such as polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), and polysorbate 80 (Tween 80). As demonstrated in the examples, these detergents are non-toxic and non-hazardous, particularly compared to Triton-X-based detergents (see FIG. 17). As a cell-lysing detergent, polysorbates such as polysorbate 20, also known as Tween 20, have been found to be particularly useful. Polysorbates are biologically non-hazardous detergents that, in addition to their cell-lysing properties, act as protective agents at the gas-liquid interface to prevent the aggregation of target molecules.

[0199] According to one embodiment, the detergent is not Triton, for example, not Triton X-100.

[0200] According to a preferred embodiment, the dissolving reagent does not contain substances of the 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated group, and preferably, the dissolving reagent does not contain any nonionic detergents that are toxic and / or harmful to the environment. According to a preferred embodiment, the dissolving reagent does not contain Triton X-100, and preferably, the dissolving reagent does not contain any nonionic detergents that are toxic and / or harmful to the environment. Avoiding these compounds has the advantage that biologically hazardous compounds are not added.

[0201] According to another embodiment, the detergent is a polyoxyethylene alkyl ether and a corresponding nonionic detergent of the Brij series, such as Triton X-100, Nonidet P40, and NP-40.

[0202] According to a preferred embodiment, the detergent has a concentration of 0.1% (v / v) to 20% (v / v), preferably a concentration selected from the following range:

[0203] i) For 1x dissolution reagent, 0.1%(v / v) to 2%(v / v);

[0204] ii) For 5x dissolution reagent, 1% (v / v) to 5% (v / v); or

[0205] iii) For 10x dissolution reagent, 4%(v / v) to 10%(v / v).

[0206] It was found that these detergent concentrations are advantageous for releasing viral vectors.

[0207] Exemplary dissolving reagents containing detergents can be found in Tables 1 and 2.

[0208] According to a specific embodiment of the method, the dissolving reagent is an acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and containing a detergent, preferably an alkyl glucoside, more preferably a polysorbate such as polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), and polysorbate 80 (Tween 80). In this embodiment, the detergent preferably has a concentration of 0.1% (v / v) to 20% (v / v), more preferably a concentration selected from the following ranges:

[0209] i) For 1x dissolution reagent, 0.1%(v / v) to 2%(v / v);

[0210] ii) For 5x dissolution reagent, 1% (v / v) to 5% (v / v); or

[0211] iii) For 10x dissolution reagent, 4%(v / v) to 10%(v / v).

[0212] In these embodiments, the viral vector may be an AAV or an adenovirus, and the cells of the cell culture are mammalian cells, preferably selected from HEK293 cells or derivatives of HEK293 cells, for example, in the case of HEK293, sub-cell lines such as HEK293, HEK293T, HEK293T / 17, ANJOU 65, HEK293H, HEK293E, HEK293-6E, HEKEBNA1-6E, HEK293F, HEK293FT, HEK293Flp-IN T-REx, HEK293FTM, HEK293S, HEK293SG, HEK293SGGD, HEK293MSR, HEK293A, or any modified variant thereof. Derivatives of HEK293 cells may also include HEK293 cells adapted to suspension culture and / or adapted to a specific type of cell culture medium.

[0213] According to a specific embodiment of the method, the dissolving reagent is an alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, e.g., 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, or greater than 8.5, and containing a detergent, preferably an alkyl glucoside, more preferably a polysorbate such as polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), and polysorbate 80 (Tween 80). In this embodiment, the detergent preferably has a concentration of 0.1% (v / v) to 20% (v / v), more preferably a concentration selected from the following ranges:

[0214] i) For 1x dissolution reagent, 0.1%(v / v) to 2%(v / v);

[0215] ii) For 5x dissolution reagent, 1% (v / v) to 5% (v / v); or

[0216] iii) For 10x dissolution reagent, 4%(v / v) to 10%(v / v).

[0217] In these embodiments, the viral vector may be an AAV or an adenovirus, and the cells of the cell culture are mammalian cells, preferably selected from HEK293 cells or derivatives of HEK293 cells, for example, in the case of HEK293, sub-cell lines such as HEK293, HEK293T, HEK293T / 17, ANJOU 65, HEK293H, HEK293E, HEK293-6E, HEKEBNA1-6E, HEK293F, HEK293FT, HEK293Flp-IN T-REx, HEK293FTM, HEK293S, HEK293SG, HEK293SGGD, HEK293MSR, HEK293A, or any modified variant thereof. Derivatives of HEK293 cells may also include HEK293 cells adapted to suspension culture and / or adapted to a specific type of cell culture medium. In such an embodiment, the method may further include the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease added to the cell culture and / or the cell lysis composition.

[0218] According to a specific embodiment of the method, the dissolving reagent has a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, e.g., 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, or greater than 8.5, and is a detergent-free alkaline dissolving reagent. In these embodiments, the viral vector may be an AAV or an adenovirus, and the cells of the cell culture are mammalian cells, preferably selected from HEK293 cells or derivatives of HEK293 cells, for example, in the case of HEK293, sub-cell lines such as HEK293, HEK293T, HEK293T / 17, ANJOU 65, HEK293H, HEK293E, HEK293-6E, HEKEBNA1-6E, HEK293F, HEK293FT, HEK293Flp-IN T-REx, HEK293FTM, HEK293S, HEK293SG, HEK293SGGD, HEK293MSR, HEK293A, or any modified variant thereof. Derivatives of HEK293 cells may also include HEK293 cells adapted to suspension culture and / or adapted to a specific type of cell culture medium. In such an embodiment, the method may further include the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease added to the cell culture and / or the cell lysis composition.

[0219] Additional exemplary dissolution reagents

[0220] According to a preferred embodiment, the dissolving reagent is an acidic dissolving reagent selected from the following:

[0221] I. 1x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0222] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer or a glycine buffer;

[0223] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0224] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0225] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0226] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0227] II. A 5x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0228] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer or a glycine buffer;

[0229] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0230] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0231] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0232] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0233] or

[0234] III. A 10x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0235] - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer or a glycine buffer;

[0236] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0237] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0238] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0239] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar.

[0240] According to a preferred embodiment, the dissolving reagent is an alkaline dissolving reagent containing a detergent selected from the following:

[0241] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0242] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0243] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0244] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0245] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0246] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0247] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0248] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0249] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0250] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0251] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0252] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0253] or

[0254] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0255] - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0256] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0257] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0258] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0259] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar;

[0260] According to a preferred embodiment, the dissolving reagent is a detergent-free alkaline dissolving reagent selected from the following:

[0261] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0262] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0263] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0264] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0265] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0266] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0267] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0268] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0269] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0270] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0271] or

[0272] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0273] - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0274] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0275] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg2+ ; and

[0276] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar.

[0277] Step (b)

[0278] According to the method for releasing a viral vector from a cell culture as disclosed herein, step (b) defines contacting the cell culture with a lysis reagent to produce a lysis composition. Contact may include adding the lysis reagent to the cell culture, adding the cell culture to the lysis culture, or combining both simultaneously. According to one embodiment, the lysis reagent is added to the cell culture, which is advantageous, for example, when the cell culture is present in a culture vessel, e.g., a bioreactor, or when the cells are present in the vessel as a cell pellet. On the other hand, the specific manner of contact does not limit the scope of the present disclosure.

[0279] Preferably, the lysis reagent is provided in liquid form and added to the cell culture in the contact step (b). This allows the lysis reagent to be added, for example, manually or in an automated manner, while the cell culture is maintained in a culture vessel, e.g., a bioreactor or a shake flask. In addition to the lysis reagent, the cell culture may also be contacted with additional compounds. These compounds may be useful for the culture of mammalian cells, for example, may be cell culture media, or may be necessary for contacting the mammalian cells with the lysis reagent. Such cell culture media are well known to those skilled in the art and do not limit the scope of this disclosure. Specific examples include the cell culture media used in the following examples.

[0280] According to a preferred embodiment, in step (b), the dissolution composition essentially comprises a compound at a concentration of a 1x dissolution reagent, which includes a 1x acidic dissolution reagent as well as a 1x detergent-containing alkaline dissolution reagent and a 1x detergent-free alkaline dissolution reagent. Since the 1x dissolution reagent is preferably provided to release a viral vector from a concentrated cell sample, such as a cell pellet, the 1x dissolution reagent is essentially not diluted or is diluted only slightly, for example, less than 20%, preferably less than 10%. As a result, the concentration defined herein for the 1x dissolution reagent essentially corresponds to the concentration obtained in the dissolution composition. In an exemplary embodiment, a 10x dissolution reagent may be mixed with the sample such that the final concentration in the dissolution composition is one-tenth of the 10x dissolution reagent, i.e., essentially corresponds to the corresponding 1x dissolution reagent. Thus, according to a preferred embodiment, the dissolution composition essentially comprises a compound at a concentration of a 1x dissolution reagent as disclosed herein. In this regard, "essentially" refers to the concentration indicated for the 1x dissolving reagent, but allows for slight dilution, for example, less than 20%, preferably less than 10%.

[0281] According to a preferred embodiment, in step (b), the dissolved composition has one of the following characteristics:

[0282] I. The above-mentioned dissolution composition has a pH of less than 5.0, preferably less than 4.5, and comprises the following:

[0283] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer or a glycine buffer;

[0284] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0285] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0286] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0287] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0288] II. The above-mentioned dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0, and comprises the following:

[0289] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0290] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0291] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0292] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0293] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0294] or

[0295] III. The above-mentioned dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0, and comprises the following:

[0296] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0297] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0298] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0299] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar.

[0300] Step (c)

[0301] According to the method for releasing a viral vector from a cell culture as disclosed herein, step (c) defines incubating a lysis composition so that the viral vector is released from the cell culture. Different incubation conditions are suitable within the framework of the present disclosure. Exemplary conditions include adjusting the temperature of the lysis composition to a range of 5°C to 50°C, preferably 25°C to 45°C, more preferably 30°C to 42°C, e.g., 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, and 42°C. According to a specific embodiment, the temperature is 37°C. Exemplary conditions further include shaking or stirring the lysis composition. For example, the dissolved composition may be shaken at 10 to 1000 rpm, preferably 20 to 500 rpm, more preferably 50 to 250 rpm. In a specific embodiment, the dissolved composition is shaken at 120 rpm. According to a specific embodiment, the dissolved composition is incubated at 37°C and shaken at 120 rpm. However, as is readily understood by those skilled in the art, different dissolution conditions are suitable and can be flexibly adjusted according to each requirement.

[0302] According to a preferred embodiment, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. According to a preferred embodiment, the incubation step (c) comprises incubating for a time selected from the range of 15 minutes to 300 minutes, preferably 20 minutes to 250 minutes, 25 minutes to 200 minutes, or more preferably 30 minutes to 150 minutes. The method according to the present disclosure has the advantage of enabling rapid and efficient release of a viral vector from a cell culture. As demonstrated in the examples, the method according to the present disclosure efficiently releases a viral vector, such as AAV, within 3.5 hours, 2 hours, and 0.5 hours. This rapid release of the viral vector improves the efficiency of the entire process.

[0303] Additional implementation example

[0304] According to a preferred embodiment, the released viral vector is purified, preferably by a single-step or multi-step approach, preferably by at least deep filtration, centrifugation, and / or sterile filtration after step (c). As demonstrated in the examples, downstream purification of the lysis composition according to the present disclosure efficiently removes host cell-associated impurities such as nucleic acids, e.g., DNA, and proteins. According to a specific embodiment, when an acidic lysis reagent is used, a significant portion of the impurities precipitates and can be easily removed in downstream purification processes such as deep filtration, centrifugation, and / or sterile filtration.

[0305] According to a preferred embodiment, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture medium, wherein the significant amount is at least 1 x 10 per mL. 11 Capsid and / or 1 x 10⁶ per mL 6It is TU. As demonstrated in the following examples, the method according to the present disclosure has the advantage of enabling such high yields to be achieved.

[0306] According to a preferred embodiment, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture in the form of a cell pellet, wherein the significant amount is at least 2 x 10 per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU. As demonstrated in the following examples, the method according to the present disclosure has the advantage of enabling such high yields to be achieved.

[0307] According to a preferred embodiment, the capsid virus vector titer and / or transduction virus vector titer are equivalent to or increased compared to Triton-X-based cell lysis buffer. As demonstrated in the following examples, the method according to the present disclosure has the advantage of enabling such high yields to be achieved without using any Triton-based detergents. Thus, the method according to the present disclosure has the advantage of avoiding the use of toxic and / or harmful detergents, such as Triton X, which has been shown below to drastically reduce cell viability (see FIG. 17).

[0308] According to one embodiment, the method comprises the following features:

[0309] i) The above dissolving reagent has a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and is a 1x acidic dissolving reagent comprising the following:

[0310] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer or a glycine buffer;

[0311] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0312] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0313] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0314] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0315] ii) In step (b), the dissolved composition has a pH of less than 5.0, preferably less than 4.5;

[0316] iii) Nuclease is not added;

[0317] iv) The above cell culture is a cell pellet;

[0318] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0319] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0320] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, preferably, the released viral vector contains at least 20% less, preferably 25% less, more preferably 30% less or 35% less host cell-derived DNA impurities compared to a method in which the lysis reagent is a neutral or alkaline lysis reagent rather than an acidic lysis reagent. In these embodiments, a significant yield of capsid viral vector titer and / or transduction viral vector titer is obtained for a cell culture, preferably a cell pellet, wherein the significant amount is at least 2 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0321] According to one embodiment, the method comprises the following features:

[0322] i) The above dissolving reagent has a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and is a 5x acidic dissolving reagent comprising the following:

[0323] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer or a glycine buffer;

[0324] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0325] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0326] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0327] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0328] ii) In step (b), the dissolved composition has a pH of less than 5.0, preferably less than 4.5;

[0329] iii) Nuclease is not added;

[0330] iv) The above cell culture is a cell culture medium;

[0331] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0332] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0333] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, preferably, the released viral vector contains at least 20% less, preferably 25% less, more preferably 30% less or 35% less host cell-derived DNA impurities compared to a method in which the lysis reagent is a neutral or alkaline lysis reagent rather than an acidic lysis reagent. In these embodiments, a significant yield of capsid viral vector titer and / or transduction viral vector titer is obtained for a cell culture, preferably a cell culture medium, wherein the significant amount is at least 1 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0334] According to one embodiment, the method comprises the following features:

[0335] i) The above dissolving reagent has a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and is a 10x acidic dissolving reagent comprising the following:

[0336] - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer or a glycine buffer;

[0337] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0338] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0339] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0340] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar;

[0341] ii) In step (b), the dissolved composition has a pH of less than 5.0, preferably less than 4.5;

[0342] iii) Nuclease is not added;

[0343] iv) The above cell culture is a cell culture medium;

[0344] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0345] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0346] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, preferably, the released viral vector contains at least 20% less, preferably 25% less, more preferably 30% less or 35% less host cell-derived DNA impurities compared to a method in which the lysis reagent is a neutral or alkaline lysis reagent rather than an acidic lysis reagent. In these embodiments, a significant yield of capsid viral vector titer and / or transduction viral vector titer is obtained for a cell culture, preferably a cell culture medium, wherein the significant amount is at least 1 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0347] According to one embodiment, the method comprises the following features:

[0348] i) The above dissolving reagent is an alkaline dissolving reagent containing a detergent, wherein the pH is greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and is a 1x alkaline dissolving reagent comprising the following:

[0349] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0350] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0351] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0352] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0353] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0354] ii) In step (b), the dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0;

[0355] iii) The above method further comprises the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease, preferably a salt-resistant nuclease, to be added to the cell culture and / or the cell lysis composition;

[0356] iv) The above cell culture is a cell pellet;

[0357] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0358] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0359] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture, preferably a cell pellet, wherein the significant amount is at least 2 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6It is TU.

[0360] According to one embodiment, the method comprises the following features:

[0361] i) The above dissolving reagent is an alkaline dissolving reagent containing a detergent, wherein the pH is greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and is a 5x alkaline dissolving reagent comprising the following:

[0362] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0363] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0364] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0365] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0366] Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0367] ii) In step (b), the dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0;

[0368] iii) The above method further comprises the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease, preferably a salt-resistant nuclease, to be added to the cell culture and / or the cell lysis composition;

[0369] iv) The above cell culture is a cell culture medium;

[0370] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0371] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0372] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture, preferably a cell culture medium, wherein the significant amount is at least 1 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0373] According to one embodiment, the method comprises the following features:

[0374] i) The above dissolving reagent is an alkaline dissolving reagent containing a detergent, wherein the pH is greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and is a 10x alkaline dissolving reagent comprising the following:

[0375] - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0376] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0377] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0378] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0379] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar;

[0380] ii) In step (b), the dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0;

[0381] iii) The above method further comprises the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease, preferably a salt-resistant nuclease, to be added to the cell culture and / or the cell lysis composition;

[0382] iv) The above cell culture is a cell culture medium;

[0383] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0384] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0385] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture, preferably a cell culture medium, wherein the significant amount is at least 1 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0386] According to one embodiment, the method comprises the following features:

[0387] i) The above dissolving reagent is a detergent-free alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and is a 1x alkaline dissolving reagent comprising the following:

[0388] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0389] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0390] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0391] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0392] ii) In step (b), the dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0;

[0393] iii) The above method further comprises the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease, preferably a salt-resistant nuclease, to be added to the cell culture and / or the cell lysis composition;

[0394] iv) The above cell culture is a cell pellet;

[0395] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293; and

[0396] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0397] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture, preferably a cell pellet, wherein the significant amount is at least 2 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0398] According to one embodiment, the method comprises the following features:

[0399] i) The above dissolving reagent is a detergent-free alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and is a 5x alkaline dissolving reagent comprising the following:

[0400] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0401] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0402] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0403] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0404] ii) In step (b), the dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0;

[0405] iii) The above method further comprises the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease, preferably a salt-resistant nuclease, to be added to the cell culture and / or the cell lysis composition;

[0406] iv) The above cell culture is a cell culture medium;

[0407] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0408] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0409] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture, preferably a cell culture medium, wherein the significant amount is at least 1 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0410] According to one embodiment, the method comprises the following features:

[0411] i) The above dissolving reagent is a detergent-free alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and is a 10x alkaline dissolving reagent comprising the following:

[0412] - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0413] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0414] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0415] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar;

[0416] ii) In step (b), the dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0;

[0417] iii) The above method further comprises the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease, preferably a salt-resistant nuclease, to be added to the cell culture and / or the cell lysis composition;

[0418] iv) The above cell culture is a cell culture medium;

[0419] v) The cell culture comprises mammalian cells, preferably HEK293 cells or derivatives of HEK293 cells; and

[0420] vi) The above virus vector is an unenveloped virus, preferably an AAV or adenovirus.

[0421] In these embodiments, preferably, the incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours. In these embodiments, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture, preferably a cell culture medium, wherein the significant amount is at least 1 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 It is TU.

[0422] According to a preferred embodiment, the method has the following features:

[0423] i) The cell culture comprises mammalian cells, preferably selected from HEK293 cells or derivatives of HEK293 cells;

[0424] ii) The incubation step (c) includes incubating for less than 4 hours, preferably less than 2 hours; and

[0425] iii) The above dissolving reagent does not contain Triton X-100, and preferably, the above dissolving reagent does not contain any nonionic detergents that are toxic and / or harmful to the environment.

[0426] Method for producing virus vectors

[0427] According to a second embodiment, a method for producing a virus vector is provided, said method comprising the following steps:

[0428] x1. A step of providing a cell culture capable of producing a viral vector;

[0429] x2. A step of producing a virus vector by culturing the above cell culture;

[0430] x3. A step of releasing a viral vector from a cell culture according to a method for releasing a viral vector from a cell culture according to a first aspect of the present invention; and

[0431] x4. Optionally, a step of purifying the released virus vector.

[0432] The method according to the second embodiment has the advantage of enabling the efficient production of a viral vector by utilizing the improved release of the viral vector from the cell culture according to the first embodiment. Thus, the advantages disclosed above can also be found in the method according to the second embodiment. Specifically, the method enables the improvement of the yield of the capsid and functional viral vector within a short incubation time of less than 4 hours (see, for example, FIGS. 3 to 10). Furthermore, the ionic strength and the type of salt have been carefully selected and screened to ensure high lysis efficiency and the stability of the viral vector. In addition, the method has the advantage that there is no need to separate cells from the cell culture before contacting the cell culture with the lysis reagent in step (b), that is, it can be applied to various samples including, for example, cell culture medium and other crude sample types (see, for example, FIGS. 11 to 14 and FIGS. 18 to 21). By omitting the step of separating cells from the surrounding liquid, for example, through centrifugation, cell lysis is simplified, and there is the advantage of being able to apply directly to the cell culture in a culture vessel, for example, a bioreactor. At the same time, no biological hazardous ingredients or method steps are included, ensuring safety for workers and the environment (see FIGS. 15 to 17).

[0433] Individual steps and preferred embodiments of the method according to the second embodiment correspond to individual steps and embodiments of the method according to the first embodiment. Accordingly, reference is made to the above disclosure, which is likewise applicable to the method according to the second embodiment. This includes, in particular but not exclusively, a viral vector, a cell culture, a buffer, a salt, a divalent cation, a detergent, a cryoprotectant, a lysis reagent comprising a nuclease / nuclease-free, and acidic and alkaline lysis reagents, and steps (a), (b), and (c). Additional features will now be described in detail.

[0434] According to a preferred embodiment, step x.3 of releasing a viral vector from a cell culture is performed by contacting a cell culture, which is a cell culture medium in a culture vessel, with a lysis reagent to produce a lysis composition, and by incubating said lysis composition in said culture vessel so that the viral vector is released from the cell culture. This embodiment has the advantage that the incubation conditions can be well defined, for example in a bioreactor, so that the temperature and / or mixing, stirring, or shaking can be easily adjusted. According to a preferred embodiment, at least one of steps x.2 and x.3 is performed in a bioreactor, and preferably both steps x.2 and x.3 are performed in a bioreactor. Exemplary conditions include adjusting the temperature of the cell culture and / or lysis composition to a range of 5°C to 50°C, preferably 25°C to 45°C, more preferably 30°C to 42°C, e.g., 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, and 42°C. According to a specific embodiment, the temperature is 37°C. Exemplary conditions further include shaking or stirring the cell culture and / or lysis composition. For example, the cell culture and / or lysis composition may be shaken at 10 to 1000 rpm, preferably 20 to 500 rpm, more preferably 50 to 250 rpm. In a specific embodiment, the cell culture and / or lysis composition is shaken at 120 rpm. According to a specific embodiment, the cell culture and / or lysis composition is incubated at 37°C and shaken at 120 rpm. However, as will be readily understood by those skilled in the art, different conditions are suitable and can be flexibly adjusted according to respective requirements.

[0435] According to an alternative embodiment, step x.3 of releasing a viral vector from a cell culture is performed by bringing a cell culture, which is a cell culture medium outside a culture vessel, into contact with a lysis reagent to produce a lysis composition, and by incubating the lysis composition outside the culture vessel so that the viral vector is released from the cell culture. For example, the cell culture may be transferred out of a culture vessel, e.g., a bioreactor, through a sterile connection, e.g., tubing, and the lysis reagent may be added inline, i.e., through coupling to the sterile connection, or from another vessel in which the lysis composition is incubated.

[0436] According to a preferred embodiment, the method comprises step x.4 of purifying the released virus vector, wherein the purification may include a single-step or multi-step approach, preferably at least deep filtration, centrifugation, and / or sterile filtration. As demonstrated in the examples, downstream purification of the lysis composition according to the present disclosure efficiently removes host cell-associated impurities such as nucleic acids, e.g., DNA, and proteins. According to a specific embodiment, when an acidic lysis reagent is used, a significant portion of the impurities precipitates and can be removed in a downstream purification process such as at least deep filtration, centrifugation, and / or sterile filtration.

[0437] According to a preferred embodiment, the method further comprises step x.5 of formulating a viral vector for gene therapy.

[0438] Reagent for releasing a viral vector from a cell culture

[0439] According to a third embodiment, a cell lysis reagent for releasing a viral vector from a cell culture, preferably a cell culture medium, is provided, said cell lysis reagent is selected from one of the following:

[0440] i) Acidic dissolving reagents selected from the following:

[0441] I. 1x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0442] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer;

[0443] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0444] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0445] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0446] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0447] II. A 5x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0448] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer;

[0449] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0450] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0451] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0452] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0453] or

[0454] III. A 10x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0455] - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer;

[0456] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0457] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0458] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0459] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose;

[0460] ii) An alkaline dissolving reagent containing a detergent selected from the following:

[0461] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0462] - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0463] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0464] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0465] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0466] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0467] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0468] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0469] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0470] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0471] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0472] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0473] or

[0474] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0475] - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0476] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0477] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0478] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0479] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose;

[0480] or

[0481] iii) A detergent-free alkaline dissolving reagent selected from the following:

[0482] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0483] - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0484] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0485] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0486] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0487] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0488] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0489] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0490] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0491] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0492] or

[0493] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0494] - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0495] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0496] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0497] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose.

[0498] The cell lysis reagent according to the third embodiment enables the efficient release of a viral vector from a cell culture and can be applied within the scope of the methods disclosed herein. Thus, the advantages disclosed above can also be found in the cell lysis according to the third embodiment. Specifically, the reagent enables improved yields of capsid and functional viral vector within a short incubation time of less than 4 hours (see, for example, FIGS. 3 to 10). Furthermore, the ionic strength and the type of salt have been carefully selected and screened to ensure high lysis efficiency and the stability of the viral vector. In addition, the reagent has the advantage that there is no need to separate cells from the cell culture before contacting the cell culture with the lysis reagent; that is, it can be applied to various samples, for example, including cell culture media and other crude sample types (see, for example, FIGS. 11 to 14 and FIGS. 18 to 21). At the same time, safety for workers and the environment is ensured as it does not contain biological hazardous components (see FIGS. 15 to 17).

[0499] Individual embodiments and preferred embodiments of the cell lysis reagent according to the third embodiment correspond to individual embodiments of the method according to the first and second embodiments. Accordingly, reference is made to the above disclosure, which is likewise applicable to the cell lysis reagent according to the third embodiment. This includes, in particular but not exclusively, viral vectors, cell cultures, buffers, salts, divalent cations, detergents, cryoprotectants, lysis reagents comprising nucleases / nuclease-free, and acidic and alkaline lysis reagents. Additional features will now be described in detail.

[0500] According to a preferred embodiment, the reagent is intended to be used to release a viral vector, preferably an adeno-associated virus (AAV) or an adenovirus (Ad), from a cell culture, preferably a cell culture medium, and optionally, the cell culture comprises mammalian cells selected from HEK293 cells or derivatives of HEK293 cells. According to a specific embodiment, the reagent is intended to be used to release a viral vector from a cell culture according to the method of the first embodiment and / or to be used to produce a viral vector according to the method of the second embodiment.

[0501] Kit for releasing a viral vector from a cell culture

[0502] According to a fourth embodiment, a kit for releasing a viral vector from a cell culture, preferably a cell culture medium, is provided, wherein the kit comprises a container containing a cell lysis reagent according to a third embodiment of the present invention, and preferably one or more of the following:

[0503] (i) Mammalian cells, preferably mammalian cells selected from HEK293 cells or derivatives of HEK293 cells;

[0504] (ii) One or more plasmids for the production of viral vectors;

[0505] (iii) Transfection reagents; and / or

[0506] (iv) Cell culture medium.

[0507] The kit for releasing a viral vector from a cell culture according to the fourth embodiment enables the efficient release of a viral vector from a cell culture and can be applied within the scope of the methods disclosed herein. Accordingly, the advantages disclosed above can also be found in the kit for releasing a viral vector from a cell culture according to the fourth embodiment. Specifically, the kit enables improved yields of capsid and functional viral vector within a short incubation time of less than 4 hours (see, for example, FIGS. 3 to 10). Furthermore, the ionic strength and the type of salt have been carefully selected and screened to ensure high dissolution efficiency and the stability of the viral vector. In addition, the kit has the advantage of not requiring the separation of cells from the cell culture before contacting the cell culture with the lysis reagent, meaning it can be applied to various samples, for example, including cell culture media and other crude sample types (see, for example, FIGS. 11 to 14 and FIGS. 18 to 21). At the same time, safety for workers and the environment is ensured as it does not contain biological hazardous components (see FIGS. 15 to 17).

[0508] Individual steps and preferred embodiments of the kit according to the fourth embodiment correspond to individual steps and embodiments of the method according to the first and second embodiments, and to the cell lysis reagent according to the third embodiment. Accordingly, reference is made to the above disclosure, which is likewise applicable to the kit according to the fourth embodiment. This includes, in particular but not exclusively, viral vectors, cell cultures, buffers, salts, divalent cations, detergents, cryoprotectants, lysis reagents including nucleases / nuclease-free, and acidic and alkaline lysis reagents. Additional features are described in detail below.

[0509] According to a preferred embodiment, the kit is intended to be used in a method for releasing a virus vector according to a first embodiment and / or in a method for producing a virus vector according to a second embodiment.

[0510] According to a preferred embodiment, the kit is intended for use in releasing a viral vector, preferably an adeno-associated virus (AAV) or an adenovirus (Ad), from a cell culture, preferably a cell culture medium, and optionally, the cell culture comprises mammalian cells selected from HEK293 cells or derivatives of HEK293 cells. According to a specific embodiment, the kit is intended for use in releasing a viral vector from a cell culture according to the method of the first embodiment and / or for use in producing a viral vector according to the method of the second embodiment.

[0511] Item according to the present disclosure

[0512] The following items provide additional advantageous embodiments of the present disclosure:

[0513] 1. A method for releasing a viral vector from a cell culture, comprising the following steps:

[0514] (a) A step of providing a dissolving reagent;

[0515] (b) a step of contacting the cell culture with the lysis reagent to produce a lysis composition; and

[0516] (c) a step of incubating the lysis composition so that the virus vector is released from the cell culture.

[0517] 2. The method of Item 1, wherein the cell culture is a cell culture medium or a cell pellet, preferably a cell culture medium.

[0518] 3. A method of item 1 or 2, wherein in step (b), it is not necessary to separate the cells of the cell culture from the surrounding liquid before contacting the cell culture with the lysis reagent.

[0519] 4. A method in which, in one or more of items 1 to 3, the dissolving reagent comprises a buffer solution having a concentration of 0.01 M to 3 M, preferably selected from the following ranges:

[0520] i) For 1x dissolving reagent, 0.05 M to 1 M;

[0521] ii) 0.3 M to 1.5 M for 5x dissolution reagent; or

[0522] iii) Preferably, for a 10x dissolving reagent, 1 M to 3 M.

[0523] 5. A method in which, in one or more of items 1 to 4, the dissolving reagent comprises a salt, preferably a salt selected from potassium chloride and sodium chloride.

[0524] 6. Method of Item 5, wherein the salt in the dissolving reagent has a concentration of 0.01 M to 5 M, preferably a concentration selected from the following range:

[0525] i) For 1x dissolving reagent, 0.05 M to 1 M;

[0526] ii) 0.3 M to 1.5 M for 5x dissolution reagent; or

[0527] iii) Preferably, for the 10x dissolving reagent, 0.8 M to 5 M or 1 M to 3 M.

[0528] 7. In one or more of items 1 to 6, the dissolving reagent is a divalent cation, preferably Mg 2+, Ca 2+ , Ba 2+ , Cu 2+ , Fe 2+ , Zn 2+ , Mn 2+ , Ni 2+ or a combination thereof, more preferably Mg 2+ , Cu 2+ , Zn 2+ , Mn 2+ , Ni 2+ or a combination thereof, most preferably Mg 2+ A method including

[0529] 8. Method of Item 7, wherein the divalent cation in the dissolving reagent has a concentration of 0.1 mM to 100 mM, preferably a concentration selected from the following range:

[0530] i) For the 1x dissolution reagent, 0.5 mM to 5 mM;

[0531] ii) For the 5x lysis reagent, 5 mM to 15 mM; or

[0532] iii) Preferably, for the 10x dissolution reagent, 15 mM to 50 mM.

[0533] 9. A method in which, in one or more of items 1 to 8, the dissolving reagent comprises a cryoprotectant, preferably a sugar, more preferably sucrose, trehalose or mannitol, most preferably sucrose.

[0534] 10. Method of Item 9, wherein the cryoprotectant in the dissolving reagent has a concentration of 1% (w / v) to 70% (w / v), preferably a concentration selected from the following range:

[0535] i) For 1x dissolution reagent, 1% (w / v) to 10% (w / v);

[0536] ii) For 5x dissolution reagent, 10% (v / v) to 35% (w / v); or

[0537] iii) For 10x dissolution reagent, 20% (w / v) to 60% (w / v).

[0538] 11. A method according to one or more of items 1 to 10, wherein the dissolving reagent is an acidic dissolving reagent, preferably having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5.

[0539] 12. The method of item 11, wherein the acidic dissolving reagent has a pH selected from the range of 1.8 to 6.0 or 2.0 to 5.5, preferably 2.75 to 5.0.

[0540] 13. A method according to item 11 or 12, wherein the acidic dissolving reagent comprises a buffer suitable for buffering the acidic dissolving reagent at an acidic pH, preferably 1.0 to 7.0, more preferably 2.0 to 6.0.

[0541] 14. A method comprising, in one or more of items 11 to 13, wherein the acidic dissolving reagent comprises an acetate buffer, a hydrochloric acid-potassium chloride buffer (HCl-KCl), a glycine buffer, a citrate buffer, a citrate-phosphate buffer, a phosphate buffer, a glycyl-glycine buffer, a sodium formate buffer, a succinate buffer, a pyridine buffer, a 2-(N-morpholino)ethanesulfonic acid (MES) buffer, a 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol (BIS-TRIS) buffer, or a combination thereof, preferably a buffer selected from acetate buffer or glycine buffer.

[0542] 15. In one or more of items 11 to 14, the dissolved composition in step (b) is:

[0543] i) Having a pH of less than 5.0, preferably less than 4.5;

[0544] ii) A method having a pH selected from the range of 2.5 to 5.0, preferably 3.5 to 4.5.

[0545] 16. A method in which a nuclease is not added to one or more of items 11 to 15.

[0546] 17. In one or more of items 11 to 16, the released virus vector is purified after step (c) preferably by at least deep filtration, centrifugation and / or sterile filtration, wherein the released virus vector contains at least 20% less, preferably 25% less, more preferably 30% less or 35% less host cell-derived DNA impurities compared to a method in which the lysis reagent is not an acidic lysis reagent but a neutral or alkaline lysis reagent.

[0547] 18. In one or more of items 11 to 17, the released virus vector is purified after step (c) preferably by at least deep filtration, centrifugation and / or sterile filtration, wherein the released virus vector contains at least 25% less, preferably 50% less, more preferably 60% less or 70% less host cell-derived protein impurities compared to a method in which the lysis reagent is not an acidic lysis reagent but a neutral or alkaline lysis reagent.

[0548] 19. A method in which, in one or more of items 1 to 10, the dissolving reagent is an alkaline dissolving reagent, preferably having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, e.g., 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, or greater than 8.5.

[0549] 20. The method of item 19, wherein the alkaline dissolving reagent has a pH selected from the range of 7.2 to 10, preferably 7.5 to 9.5.

[0550] 21. A method according to item 19 or 20, wherein the alkaline dissolving reagent comprises a buffer solution suitable for buffering the alkaline dissolving reagent at an alkaline pH, preferably a buffer solution capable of buffering at a pH selected from the range of 7.2 to 9.5.

[0551] 22. A method according to one or more of items 19 to 21, wherein the alkaline dissolving reagent comprises a buffer selected from tris(hydroxymethyl)-aminomethane (TRIS) buffer, 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer, phosphate buffer, glycine-sodium hydroxide buffer, 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) buffer, TES buffer, DIPSO buffer, TAPSO buffer, triethanolamine buffer, HEPPSO buffer, POPSO buffer, TRICINE buffer, HEPPS buffer, EPPS buffer, BICIN buffer, TAPS buffer, AMPSO buffer, taurine buffer, CHES buffer, AMP buffer, CAPSO buffer, or a combination thereof, preferably a buffer selected from TRIS buffer or BTP buffer.

[0552] 23. A method in which, in one or more of items 19 to 22, the dissolved composition in step (b) has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0.

[0553] 24. A method in which, in one or more of items 19 to 23, the dissolved composition in step (b) has a pH selected from the range of 7.2 to 10.0, preferably 7.5 to 9.5.

[0554] 25. A method according to one or more of items 19 to 24, wherein the method further comprises the step of providing the lysis reagent, the cell culture and / or the cell lysis composition, preferably a nuclease added to the cell culture and / or the cell lysis composition.

[0555] 26. In item 25, the above nuclease is salt-resistant, method.

[0556] 27. A method according to one or more of items 1 to 26, wherein the dissolving reagent comprises a detergent, preferably a nonionic detergent, more preferably a nonionic detergent that is not classified as toxic and / or harmful to the environment and / or a nonionic detergent that is not toxic and / or harmful to the environment.

[0557] 28. In item 27, the detergent is selected from one or more of Tween, Triton, Nonidet, Igepal, or Tergitol, preferably from Tween.

[0558] 29. Method according to item 27 or 28, wherein the detergent is an alkyl glucoside, preferably a polysorbate such as polysorbate 20 (Tween 20), polysorbate 40 (Tween 40) and polysorbate 80 (Tween 80).

[0559] 30. A method in which, in one or more of items 27 to 29, the detergent is a corresponding nonionic detergent of the Brij series and polyoxyethylene alkyl ether such as Triton X-100, Nonidet P40, NP-40.

[0560] 31. A method in which, in one or more of items 27 to 30, the detergent has a concentration of 0.1% (v / v) to 20% (v / v), preferably a concentration selected from the following range:

[0561] i) For 1x dissolution reagent, 0.1%(v / v) to 2%(v / v);

[0562] ii) For 5x dissolution reagent, 1% (v / v) to 5% (v / v); or

[0563] iii) For 10x dissolution reagent, 4%(v / v) to 10%(v / v).

[0564] 32. In one or more of Item 1 or 31, the dissolving reagent is one of the following: Method:

[0565] i) Acidic dissolving reagents selected from the following:

[0566] I. 1x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0567] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer or a glycine buffer;

[0568] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0569] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0570] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0571] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0572] II. A 5x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0573] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer or a glycine buffer;

[0574] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0575] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0576] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0577] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0578] or

[0579] III. A 10x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0580] - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer or a glycine buffer;

[0581] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0582] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0583] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0584] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar;

[0585] ii) An alkaline dissolving reagent containing a detergent selected from the following:

[0586] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0587] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0588] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0589] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0590] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0591] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0592] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0593] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0594] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0595] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0596] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0597] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0598] or

[0599] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0600] - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0601] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0602] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0603] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0604] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar;

[0605] or

[0606] iii) A detergent-free alkaline dissolving reagent selected from the following:

[0607] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0608] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0609] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0610] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0611] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0612] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0613] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0614] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0615] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0616] - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar;

[0617] or

[0618] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0619] - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0620] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0621] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0622] - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar.

[0623] 33. A method according to one or more of items 1 to 32, wherein in step (b), the dissolving composition essentially comprises a compound at a concentration of 1x dissolving reagent, preferably essentially at a concentration according to item 32, or the dissolving composition has one of the following characteristics:

[0624] I. The above-mentioned dissolution composition has a pH of less than 5.0, preferably less than 4.5, and comprises the following:

[0625] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer or a glycine buffer;

[0626] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0627] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0628] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0629] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0630] II. The above-mentioned dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0, and comprises the following:

[0631] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0632] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0633] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0634] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0635] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar;

[0636] or

[0637] III. The above-mentioned dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0, and comprises the following:

[0638] - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer;

[0639] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0640] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0641] - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar.

[0642] 34. In one or more of items 1 to 33, the incubation step (c) comprises the following:

[0643] - Incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours; and / or

[0644] - Incubating for a time selected from the range of 15 to 300 minutes, preferably 20 to 250 minutes, 25 to 200 minutes, or more preferably 30 to 150 minutes.

[0645] 35. A method in which, in one or more of items 1 to 34, the cell culture is not subjected to ultrasonic treatment, high-pressure homogenization, or freeze-thaw.

[0646] 36. A method in which, in one or more of items 1 to 35, the cell culture does not undergo centrifugation, cell pelleting, or exchange of the liquid surrounding the cells of the cell culture prior to steps (a), (b), and (c).

[0647] 37. A method in which, in one or more of items 1 to 36, the released virus vector is preferably purified by a single-step or multi-step approach, preferably by at least deep filtration, centrifugation, and / or sterile filtration after step (c).

[0648] 38. In one or more of items 1 to 37, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained with respect to the cell culture medium, wherein the significant amount is at least 1 x 10⁻¹⁰ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 TU, method.

[0649] 39. In one or more of items 1 to 38, a significant yield of capsid virus vector titer and / or transduction virus vector titer is obtained for a cell culture that is a cell pellet, wherein the significant amount is at least 2 x 10 per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 TU, method.

[0650] 40. In one or more of items 1 to 39, the capsid virus vector titer and / or transduction virus vector titer is equivalent to or increased compared to Triton-X-based cell lysis buffer.

[0651] 41. A method for producing a virus vector comprising the following steps:

[0652] x.1 A step of providing a cell culture capable of producing a viral vector;

[0653] x.2 A step of producing a virus vector by culturing the above cell culture;

[0654] x.3 A step of releasing a viral vector from a cell culture according to one or more of items 1 to 39; and

[0655] x.4 Optionally, a step of purifying the released virus vector.

[0656] 42. A method according to Item 41, wherein step x.3 of releasing a virus vector from a cell culture is performed by bringing a cell culture, which is a cell culture medium in a culture vessel, into contact with a lysis reagent to produce a lysis composition, and incubating the lysis composition in the culture vessel so that the virus vector is released from the cell culture.

[0657] 43. In one or more of items 41 to 42, the method comprises the step of purifying a virus vector, wherein the purification is a single-step or multi-step approach, preferably comprising at least deep filtration, centrifugation and / or sterile filtration.

[0658] 44. A method according to one or more of items 41 to 43, wherein the method further comprises step x.5 of formulating a viral vector for gene therapy.

[0659] 45. A method in which, in one or more of items 41 to 44, at least one of steps x.2 and x.3 is carried out in a bioreactor, preferably both steps x.2 and x.3 are carried out in a bioreactor.

[0660] 46. ​​A method according to one or more of items 1 to 45, wherein the virus vector is mainly present inside a cell and is preferably selected from adeno-associated virus (AAV) or adenovirus (Ad).

[0661] 47. A method according to one or more of items 1 to 46, wherein the cell culture comprises mammalian cells.

[0662] 48. In item 47, the mammalian cell is modified to be configured to produce a viral vector, preferably an AAV.

[0663] 49. Method of Item 47 or 48, wherein the mammalian cell is selected from HEK293 cells or derivatives of HEK293 cells.

[0664] 50. In one or more of items 1 to 49, the cell culture is present widely A method comprising cells that can be cultured in a state.

[0665] 51. A cell lysis reagent for releasing a viral vector from a cell culture, preferably from a cell culture medium, selected from one of the following:

[0666] i) Acidic dissolving reagents selected from the following:

[0667] I. 1x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0668] - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer;

[0669] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0670] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0671] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0672] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0673] II. A 5x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0674] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer;

[0675] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0676] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0677] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0678] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0679] or

[0680] III. A 10x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following:

[0681] - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer;

[0682] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0683] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0684] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0685] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose;

[0686] ii) An alkaline dissolving reagent containing a detergent selected from the following:

[0687] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0688] - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0689] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0690] - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate;

[0691] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0692] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0693] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0694] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0695] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0696] - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate;

[0697] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0698] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0699] or

[0700] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0701] - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0702] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0703] - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate;

[0704] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0705] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose;

[0706] or

[0707] iii) A detergent-free alkaline dissolving reagent selected from the following:

[0708] I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0709] - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0710] - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride;

[0711] - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and

[0712] - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose;

[0713] II. A 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0714] - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0715] - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride;

[0716] - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and

[0717] - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose;

[0718] or

[0719] III. A 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following:

[0720] - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer;

[0721] - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride;

[0722] - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and

[0723] - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose.

[0724] 52. A reagent according to item 51 for use in releasing a viral vector, preferably an adeno-associated virus (AAV) or an adenovirus (Ad) from a cell culture, preferably a cell culture medium, wherein the cell culture optionally comprises mammalian cells selected from HEK293 cells or derivatives of HEK293 cells.

[0725] 53. A kit for releasing a virus vector from a cell culture, preferably from a cell culture medium, wherein the kit comprises a container containing a cell lysis reagent according to item 50.

[0726] 54. A kit of Item 53 that additionally includes one or more of the following:

[0727] (i) Mammalian cells, preferably mammalian cells selected from HEK293 cells or derivatives of HEK293 cells;

[0728] (ii) One or more plasmids for the production of viral vectors;

[0729] (iii) Transfection reagents; and / or

[0730] (iv) Cell culture medium.

[0731] Throughout this specification, where a method, reagent, kit, or use is described as having, including, or encompassing a specific component or step, additionally, it is considered that the method, reagent, kit, or use of the present invention is essentially composed of or composed of the described component or step.

[0732] In this application, where an element or component is referred to as being included in and / or selected from a list of described elements or components, it should be understood that the element or component may be any one of the described elements or components, or that the element or component may be selected from a group consisting of two or more of the described elements or components.

[0733] The terms "a," "an," and "the" and similar designations used in the context describing the invention (particularly in the context of the claims) shall be interpreted as encompassing both singular and plural forms, unless otherwise indicated herein or clearly contradictory in the context.

[0734] The use of the terms "include," "includes," "including," "have," "has," "having," "contain," "contains," or "containing," including their grammatical equivalents, should be understood as generally open and non-restrictive, and not to exclude, for example, any additional elements or steps not described, unless otherwise specifically stated or understood from the context.

[0735] Where the term "about" or "approximately" is used before a quantitative value, the present invention includes the specific quantitative value itself, unless otherwise specifically stated. As used herein, the term "about" refers to a variation of ±10% from a nominal value unless otherwise indicated or inferred.

[0736] Furthermore, as used herein, "and / or" refers to and encompasses all possible combinations of one or more related enumerated items, as well as the absence of combinations when interpreted alternatively ("or"). The use of alternatives (e.g., "or") should be understood to mean any one, both, or any combination thereof of the alternatives.

[0737] All cited literature is included by reference.

[0738] All individual embodiments and aspects disclosed herein may be combined with one another within the framework and context of this disclosure. The embodiments disclosed herein are merely exemplary, and it will be understood that any feature presented for a particular exemplary embodiment may be used alone with this disclosure, in combination with any feature presented for the same or other particular exemplary embodiments, and / or in combination with any other feature not mentioned. It will be further understood that any feature presented for an exemplary embodiment of a particular category may be used in a corresponding manner in any other exemplary embodiment of any other category.

[0739] Examples

[0740] It should be understood that the following examples are for illustrative purposes only and should not be construed as limiting the invention in any way. The following examples demonstrate the advantages of the lysis reagent of the present invention, as well as its application within the framework of the methods disclosed herein, its use for releasing viral vectors, preferably adeno-associated viruses (AAV) or adenoviruses (Ad), from cell cultures, and the kit according to the present disclosure. Specifically, the examples demonstrate that increased extraction of viral vectors can be achieved compared to standard lysis reagents such as "prior art lysis reagents." This increase is achieved by improving the efficiency of cell lysis, while reducing the formation of viral vector aggregates, such as AAV vector aggregates, and facilitating their removal by precipitation of host cell-associated impurities.

[0741] Materials and Methods

[0742] Cell lysis workflow

[0743] The cell lysis reagents were tested using suspension-cultured HEK293 cells (Expi293FTM, Thermo Fisher Scientific Inc.) that transiently produce viral vectors such as AAV2 and adenovirus. An exemplary workflow of the downstream process, including viral vector production, cell lysis, and clarification and purification according to the examples, can be found in Fig. 1. The cell lysis process is illustrated in Fig. 2 and begins by adding the cell lysis reagent to the HEK293 cells. In particular, most cell lysis reagents, including standard lysis reagents such as "prior art cell lysis reagents" (e.g., see Fedosyuk et al., 2019, Vaccine, Vol. 37, pp. 6951-6961), require the addition of nucleases for optimal performance. In the case of the lysis reagents according to the present disclosure, nucleases are not required in some cases, such as in the case of acidic lysis reagents (see Table below). After an incubation period of 0.5 to 3.5 hours at 37℃ and 120 rpm, the next step involves purification through sterile filtration using a low-protein binding filtration device. Subsequently, the collected filtrate is analyzed using various quantitative methods.

[0744] As a model for AAV, two different serotypes, AAV2 and AAV8, were produced by transiently transfecting cells with one or more plasmids. As a model for the adenovirus (Ad) vaccine, the ChAdOx1 nCoV-19 adenovirus vector was used. This Ad vector is based on the modified Y25 chimpanzee adenovirus serotype and was developed at the Jenner Institute of Oxford University (Joe et al. 2021 (bioRxiv 2021.12.22.473478)). Transient production was initiated by infecting HEK293 cell cultures with the purified virus. After cell transfection (AAV) or infection (Ad), culture was continued for the prescribed viral vector production time, typically 48 to 72 hours. Immediately thereafter, the cell cultures were used for lysis experiments.

[0745] quantification of functional titer for AAV2

[0746] The determination of active AAV2 vector yield is performed through AAV2 transduction assays, also known as potency, activity, or infectivity tests or analyses. This quantitative method serves to measure the potency of the AAV2 vector. Regulatory agencies such as the FDA and Ph. Eur. require potency testing for cell and gene therapy products, making it an essential aspect of the development process.

[0747] The potency test performed in this study complies with FDA requirements for potency testing of cell and gene therapy products. This is an in vitro assay that quantifies transplanted gene expression after evaluating the transfer of genetic material from a viral vector to an acceptable cell line. This robust and reliable assay provides valuable insights into the efficacy and functionality of the AAV vector being evaluated.

[0748] For AAV2 transduction analysis, adherent HEK293 cells were seeded into 24-well or 96-well plates and immediately transduced with serially diluted AAV2 filtrate. After a 72-hour incubation period, GFP expression was analyzed using the Incucyte® Live-Cell Analysis System (Sartorius Stedim Biotech GmbH).

[0749] Capsid titer quantification

[0750] To quantify AAV2 capsid titers, the binding rate of serially diluted AAV2 clarified cell lysates was determined at 1800 seconds using the Octet® AAVX biosensor (Sartorius Stedim Biotech GmbH) on the Octet® Bio Layer Interferometry platform (Sartorius Stedim Biotech GmbH). The binding rate was compared to the binding rates of commercially available AAV2 and AAV8 standards (Progen).

[0751] Adenovirus (Ad) samples were loaded onto an Octet® ProA biosensor (Sartorius Stedim Biotech GmbH) pre-coated with an Ad-specific antibody (Abcam). Ad probe preparation and titer quantification were performed according to the protocol published by Kruse et al., 2023.

[0752] (https: / / www.sartorius.com / en / pr / octet / adenovirus-quantitation-application-note?utm_source=marketo&utm_medium=email&utm_campaign=octet-bioprocessing&utm_term=adenovirus&utm_content=application-note%C2%A0#id-1487168).

[0753] Dissolving reagent

[0754] A common example of a standard lysis reagent is the "prior art cell lysis reagent," which has become a laboratory standard as a widely used detergent-mediated cell lysis buffer. This was disclosed, for example, in Joe et al. 2021 (bioRxiv 2021.12.22.473478) and has become a laboratory standard. The composition of the "prior art cell lysis reagent" can be found in Table 1. This buffer was used as a reference lysis reagent for comparison with the novel lysis reagent disclosed herein.

[0755] Another standard lysis reagent used in this study is 2-[4-(2,4,4-trimethylpentane-2-yl)phenoxy]ethanol, known as the Triton X-100-containing lysis reagent ("TRT"). Triton X-100 and its derivatives were commonly used in the past for AAV extraction, but due to biological hazards, they are listed on the REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) list, and their use in the European Union is restricted or prohibited. The composition of the "TRT" cell lysis reagent can be found in Table 1.

[0756] The additional reference cell lysis reagent used in the following examples is CelLytic TM M(C1, Sigma Aldrich) and CelLytic TM Selected from M (C2, both from Sigma Aldrich) and M-PER® (Thermo Fisher Scientific), all of which are used in accordance with the manufacturer's instructions.

[0757] The novel dissolution reagent according to the present disclosure is typically formulated by combining a stock solution of a buffer salt adjusted to an appropriate pH (e.g., acetate buffer at pH 4) and a solution of a neutral salt (e.g., potassium chloride and magnesium chloride), taking into account the individual solubility of the salts. For supplementation of sucrose and polysorbate 20, a stock solution of sucrose and polysorbate 20 is used.

[0758] tablet

[0759] The clarified AAV2 lysate was loaded onto a 1 ml pre-packed POROSTM CaptureSelect™ AAVX column. The affinity purification process was The procedure was performed on a KTATM pure 150 system according to the manufacturer's instructions. After buffering the eluent with 20 mM BisTRISPropane, pH 9, anion exchange chromatography was performed using a 1 ml pre-packed POROSTM GoPureTM HQ column. Anion exchange purification was It was performed on a KTATM pure 150 system according to the manufacturer's instructions.

[0760] SDS-PAGE

[0761] The clarified AAV2 lysate was characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using Mini-PROTEAN® TGX Precast 4-20% gel according to the manufacturer's instructions.

[0762] Other quantitative methods

[0763] Viable cell concentration (VCC), total cell concentration (TCC), viability, and mean cell diameter were analyzed using an automated Trypan Blue assay-based cell counting system (Cedex HiRes Analyzer, Roche, Germany). A nephelometer with a small 10 mL cuvette (TL2350, Hach, Germany) was used for turbidity measurements.

[0764] Example 1: Acidic dissolving reagent for dissolving HEK293 producing AAV2

[0765] In Example 1, the acidic lysis reagent according to the present disclosure was used to lyse HEK293 cells cultured in suspension after the culture and production of AAV2. Cell lysis was performed on harvested cells at 300 g for 5 minutes. After adding 1x cell lysis buffer to the cell pellet, an incubation step was performed for 0.5–3.5 hours. Finally, a clarification step was performed using a low-protein-coupled filtration device. Examples of acidic cell lysis reagents tested are listed in Table 1, all of which have an acidic pH much lower than pH 7.0. Furthermore, the acidic lysis reagent contains a detergent, specifically polysorbate 20. However, other detergents, particularly other polysorbates, may also be applied as the detergent for the acidic lysis reagent disclosed herein. As demonstrated below, the acidic lysis reagents disclosed herein address technical problems typically encountered in cell lysis, including low cell lysis efficiency and / or long lysis duration, high AAV vector agglutination, high host cell impurity content, and the potential need for nuclease treatment and / or other physical or mechanical lysis steps (e.g., freeze-thaw cycles).

[0766]

[0767] AAV2 functional titer

[0768] AAV2 functional titers were determined using the aforementioned incucyte-based transduction assay. For comparison, the "prior art cell lysis reagent" was used as a reference lysis reagent. The results are shown in Figure 3.

[0769] As can be seen in FIG. 3, the functional potency is very high in the acidic dissolving reagent according to the present disclosure, 4x10 7 Up to 6x10 7 While it is TU / mL, the functional titer of the reference dissolution reagent is 1x10 7 It was less than TU / mL. These results were consistently obtained for different salt concentrations ranging from 50 to 500 mM and incubation periods ranging from 0.5 to 2 hours. In the acidic lysis reagents tested, Tween20 was used as a detergent, and the pH of the reagent was set to 4.0. Thus, the above results indicate that the acidic lysis reagent according to the present disclosure enables highly efficient cell lysis and increased functional potency yield.

[0770] AAV2 capsid titer

[0771] AAV2 capsid titers were determined after cell lysis and clarification using the Octet® AAVX biosensor as described above. For comparison, the "prior art cell lysis reagent" was used as a reference lysis reagent. The results are shown in Figure 4.

[0772] As can be seen in FIG. 4, the capsid titer is very high in the acidic dissolution reagent according to the present disclosure, 1.0 x 10⁻⁶ 13 Up to 1.5x10 13 While the capsid / mL value is capsid, the capsid titer of the standard lysis reagent is 2.0 x 10⁻⁶ 12The capsid / mL was less than 1 / mL. These results were consistently obtained for different salt concentrations ranging from 50 to 500 mM and incubation periods ranging from 0.5 to 2 hours. Tween20 was used as a detergent in the acidic lysis reagents tested, and the pH of the reagent was set to 4.0. Overall, the results indicate that the acidic lysis reagent according to the present disclosure enables highly efficient cell lysis and increased capsid potency yield.

[0773] Filtration of dissolved substances

[0774] To test whether the crude lysate allows filtration, the crude lysate of HEK293 cells (Expi293, Thermo Fisher Scientific) producing the AAV2 vector was sterile filtered through a 0.22 μm CA Spin-X filter (Sigma Aldrich). The variables of the cell lysis conditions (pH, salt molar concentration, incubation time, and addition of detergent) are shown in Figure 5 along with photographs of the spin filter. The cell lysis setup shown was performed without the nuclease digestion step.

[0775] The photograph in FIG. 5 shows that when the acidic dissolving reagent according to the present disclosure is added to cells, a dissolving composition that is very easy to filter is formed. Specifically, a clear permeate containing AAV2 is formed, while precipitated impurities, such as host cell-associated impurities, remain on the filter. In contrast, the pH 8 dissolving reagent results in a dissolving product with high viscosity, requiring additional nuclease digestion to facilitate the filtration step (see FIG. 5 for the setup N25 without the nuclease digestion step).

[0776] Analysis of host cell impurities

[0777] To determine host cell-related impurities, SDS-PAGE analysis was performed on sterile filtered crude lysates of HEK293 (Expi293) cells producing the AAV2 vector under reducing and denaturing conditions. Protein bands on the gel were visualized by Coomassie blue staining. Variables of cell lysis conditions (pH, salt molar concentration, incubation time, and addition of detergent) are shown in Table 1 for acidic lysis reagents. M in lanes 1 and 13 represents the PageRuler™ unstained protein ladder (Thermo Fisher Scientific).

[0778] The gel bands shown in Fig. 6 demonstrate that acidic pH significantly reduces host cell-associated impurities compared to alkaline pH dissolution reagents. Thus, the results indicate that lower pH is advantageous for increasing the purity of the viral vector (in this case, AAV2), thereby leading to more efficient downstream purification as well as higher safety of the viral vector product. Furthermore, the gel bands correlate with better filtration properties (see Fig. 5), observed in that better-filtered samples contain fewer host cell-associated impurities. In addition, these advantageous properties of the acidic dissolution reagents according to the present disclosure were consistently observed for different salt concentrations ranging from 50 to 500 mM, and higher salt concentrations appear to contain slightly fewer host cell-associated impurities.

[0779] conclusion

[0780] Example 1 demonstrates that the acidic dissolving reagent according to the present disclosure solves the following technical problems by implementing several key improvements:

[0781] i) Enhanced cell lysis efficiency: Acidic cell lysis reagents ensure effective cell destruction, thereby improving the extractability of intracellular AAV vectors. Their use resulted in a yield of fully active AAV vectors up to 4.5 times higher than that obtained using standard lysis reagents (see Fig. 3). Higher AAV vector yields mean that more drugs can be obtained from the same production process, thereby increasing overall productivity and reducing the cost per unit.

[0782] ii) Facilitated removal of host cell impurities: Due to their low pH, acidic cell lysis reagents facilitate the precipitation and efficient removal of host cell-related impurities, leading to improved purification and potentially higher-quality end products. The removal of host cell proteins was confirmed by densitometry analysis of Coomassie blue-stained SDS-PAGE gels (see Fig. 6 for setups N1, N5, and N9). Acidic reagents enable the precipitation of most protein and nucleic acid impurities during the cell lysis step while maintaining high target molecule yields and functionality. As a result, a end product of higher purity can potentially be obtained with fewer steps required in the downstream process. This reduces product loss and contributes to more efficient purification.

[0783] iii) Reduction of AAV vector aggregates: Improved filtration and purity indicate that the acidic cell lysis reagent minimizes the formation of AAV vector aggregates, enabling an easier purification process and possibly higher titers.

[0784] iv) Elimination of the need for nucleases: Acidic cell lysis reagents eliminate the addition of nucleases during or after cell lysis. Due to the low pH of the reagent, and possibly due to the precipitation of host cell proteins and nucleic acids, the cell lysate exhibits reduced viscosity. This enables efficient filtration without the need for additional nuclease degradation (see Fig. 5 for settings N2, N5, and N6). Conversely, when using a pH 8 reagent for cell lysis, the resulting lysate has high viscosity and requires additional nuclease degradation to facilitate the filtration step (see Fig. 5 for setting N25 without a nuclease degradation step). Furthermore, nuclease degradation can be a cause of high costs associated with the manufacture of biopharmaceuticals. Therefore, the elimination of the need for nucleases reduces related costs.

[0785] v) Shorter Incubation Time: Acidic cell lysis reagents enable efficient cell lysis and AAV vector extraction within 30 minutes, which is significantly shorter than standard cell lysis protocols. Reducing incubation time in the production process has the potential to lower overall production costs. Optimized cell lysis reagents enable shorter cell lysis and extraction times. These time-saving aspects can lead to significant cost reductions by decreasing the total time required for the production cycle.

[0786] vi) No biological hazard: The above reagent is formulated using ingredients that are safe for humans and the environment, eliminating potential biological hazard risks associated with the use of, for example, Triton-X100.

[0787] Overall, the improved viral vector extraction efficiency provided by the acidic dissolution reagent of the present disclosure has the potential to significantly impact the manufacturing costs of viral vector-based medicines. By increasing yield and simplifying the production process, these technical and economic advancements have the ability to make viral vector-based therapies more accessible and affordable for patients who need them.

[0788] Example 2: Alkaline dissolving reagent containing a detergent for dissolving HEK293 to produce AAV2

[0789] In Example 2, an alkaline lysis reagent containing a detergent according to the present disclosure was used to lyse HEK293 cells cultured in suspension after the culture and production of AAV2. Cell lysis was performed on harvested cells at 300 g for 5 minutes. After adding 1x cell lysis buffer supplemented with salt-activating nucleases to the cell pellet, an incubation step was performed for 0.5–3.5 hours. Finally, a clarification step was performed using a low-protein-coupled filtration device. Examples of tested alkaline cell lysis reagents containing recommended nucleases are listed in Table 2, all of which have an alkaline pH much higher than pH 7.0. Furthermore, the alkaline lysis reagent contains a detergent, specifically polysorbate 20, and a salt-tolerant nuclease was added to the lysis composition. However, other detergents, particularly other polysorbates, may also be applied as the detergent for the alkaline lysis reagent disclosed herein. As demonstrated below, the alkaline lysis reagents disclosed herein address technical problems typically encountered in cell lysis, including low cell lysis efficiency and / or long lysis duration, high AAV vector aggregation, and the potential need for physical or mechanical lysis steps (e.g., freeze-thaw cycles).

[0790]

[0791] AAV2 functional titer

[0792] AAV2 functional titers were determined using the aforementioned incucyte-based transduction assay. For comparison, the "prior art cell lysis reagent" was used as the reference lysis reagent. The results are shown in Figure 7.

[0793] As can be seen in FIG. 7, the functional potency is very high in the alkaline dissolving reagent according to the present disclosure, 5x10 7 Up to 8.5x10 7 While it is TU / mL, the functional titer of the reference dissolution reagent is 1x10 7 It was less than TU / mL. These results were consistently obtained for different salt concentrations ranging from 275 to 1000 mM, incubation periods ranging from 0.5 to 3.5 hours, and pH ranging from 8 to 9. In the alkaline lysis reagents tested, Tween20 was used as a detergent, and a salt-tolerant nuclease was added to the lysis composition. Thus, the results indicate that the alkaline lysis reagent containing the detergent according to the present disclosure enables highly efficient cell lysis and increased functional potency yield.

[0794] AAV2 capsid titer

[0795] AAV2 capsid titers were determined after cell lysis and clarification using the Octet® AAVX biosensor as described above. For comparison, the "prior art cell lysis reagent" was used as a reference lysis reagent. The results are shown in Figure 8.

[0796] As can be seen in FIG. 8, the capsid titer is very high in the alkaline dissolving reagent containing the detergent according to the present disclosure, 4x10 12 Up to 16x10 12 While the capsid / mL value is capsid, the capsid titer of the standard lysis reagent is 2.0 x 10⁻⁶ 12The capsid / mL was less than 1 mL. These results were consistently obtained for different salt concentrations ranging from 275 to 1000 mM, incubation periods ranging from 0.5 to 3.5 hours, and pH ranging from 8 to 9. In the alkaline lysis reagents tested, Tween20 was used as a detergent, and a salt-tolerant nuclease was added to the lysis composition. Overall, the results indicate that the alkaline lysis reagent containing the detergent according to the present disclosure enables highly efficient cell lysis and increased capsid potency yield.

[0797] conclusion

[0798] Example 2 demonstrates that an alkaline dissolving reagent containing a detergent according to the present disclosure solves the following technical problems by implementing several key improvements:

[0799] i) Increased Yield: Alkaline cell lysis reagents containing detergent ensure effective cell destruction, thereby improving the extractability of intracellular AAV vectors (see Fig. 7). By improving AAV vector extraction efficiency using the developed cell lysis reagent, it is possible to significantly reduce the manufacturing cost of AAV-based drugs. The improved extraction efficiency, demonstrated by AAV2 transduction assay results, leads to a higher yield of active AAV vectors. Higher AAV vector yield means that more drugs can be obtained from the same production process, thereby increasing overall productivity and reducing the cost per unit.

[0800] ii) Reduction of AAV vector aggregates: Higher titers indicate that alkaline cell lysis reagents minimize the formation of AAV vector aggregates, enabling an easier purification process.

[0801] iii) No biological hazard: The above reagent is formulated using ingredients that are safe for humans and the environment, eliminating potential biological hazard risks associated with the use of, for example, Triton-X100.

[0802] iv) Shorter cell lysis process: Optimized cell lysis reagents enable shorter cell lysis and extraction times. These time-saving aspects can lead to significant cost reductions by reducing the total time required for the production cycle.

[0803] Overall, the improved viral vector extraction efficiency provided by the alkaline dissolution reagent containing the detergent of the present disclosure has the potential to have a significant impact on the manufacturing cost of viral vector-based medicines. By increasing yield and simplifying the production process, these technical and economic advancements have the ability to make viral vector-based therapies more accessible and affordable for patients who need them.

[0804] Example 3: Detergent-free alkaline dissolving reagent for dissolving HEK293 to produce AAV2

[0805] In Example 3, the detergent-free alkaline lysis reagent according to the present disclosure was used to lyse HEK293 cells in suspension culture after the culture and production of AAV2. Cell lysis was performed on harvested cells at 300 g for 5 minutes. After adding 1x cell lysis buffer supplemented with salt-active nuclease to the cell pellet, an incubation step was performed for 0.5–3.5 hours. Finally, a clarification step was performed using a low-protein-coupled filtration device. Examples of tested alkaline cell lysis reagents are listed in Table 3, all of which have an alkaline pH much higher than pH 7.0. Furthermore, the alkaline lysis reagents do not contain detergent, and salt-tolerant nucleases were added to the lysis composition. As demonstrated below, the detergent-free alkaline lysis reagent disclosed herein addresses technical problems typically encountered in cell lysis, including low cell lysis efficiency and / or long lysis duration, high AAV vector aggregation, and the potential need for physical or mechanical lysis steps (e.g., freeze-thaw cycles).

[0806]

[0807] AAV2 functional titer

[0808] AAV2 functional titers were determined using the aforementioned incucyte-based transduction assay. For comparison, the prior art cell lysis reagent was used as the reference lysis reagent. The results are shown in Figure 9.

[0809] As can be seen in FIG. 9, the functional potency is very high in the detergent-free alkaline dissolving reagent according to the present disclosure, 6x10 7 to 9x10 7 While it is TU / mL, the functional titer of the reference dissolution reagent is 1x10 7 It was less than TU / mL. These results were consistently obtained for different salt concentrations in the range of 275 to 500 mM, incubation periods in the range of 0.5 to 3.5 hours, and pH 8. In the alkaline lysis reagents tested, salt-tolerant nucleases were added to the lysis composition. Thus, the results indicate that the detergent-free alkaline lysis reagent according to the present disclosure enables highly efficient cell lysis and increased functional potency yields.

[0810] AAV2 capsid titer

[0811] AAV2 capsid titers were determined after cell lysis and clarification using the Octet® AAVX biosensor as described above. For comparison, the "prior art cell lysis reagent" was used as a reference lysis reagent. The results are shown in Figure 10.

[0812] As can be seen in FIG. 10, the capsid titer is very high in the detergent-free alkaline dissolving reagent according to the present disclosure, 8x10 12 Up to 15x10 12 While the capsid / mL value is 2x10, the capsid titer of the standard lysis reagent is 2x10 12The capsid / mL was less than 1 / mL. These results were consistently obtained for different salt concentrations ranging from 275 to 500 mM, incubation periods ranging from 0.5 to 3.5 hours, and pH 8. In the alkaline lysis reagents tested, salt-tolerant nucleases were added to the lysis composition. Overall, the results indicate that the detergent-free alkaline lysis reagent according to the present disclosure enables highly efficient cell lysis and increased capsid potency yield.

[0813] conclusion

[0814] Example 3 demonstrates that the detergent-free alkaline dissolving reagent according to the present disclosure solves the following technical problems by implementing several key improvements:

[0815] i) Increased Yield: The detergent-free alkaline cell lysis reagent ensures effective cell destruction, thereby improving the extractability of intracellular AAV vectors (see Fig. 9). By improving AAV vector extraction efficiency using the developed cell lysis reagent, it is possible to significantly reduce the manufacturing cost of AAV-based drugs. The improved extraction efficiency, demonstrated by AAV2 transduction assay results, leads to a higher yield of active AAV vectors. Higher AAV vector yield means that more drugs can be obtained from the same production process, thereby increasing overall productivity and reducing the cost per unit.

[0816] ii) Reduction of AAV vector aggregates: Higher titers indicate that alkaline cell lysis reagents minimize the formation of AAV vector aggregates, enabling an easier purification process.

[0817] iii) Detergent-free: The above reagent is formulated without any added detergent, enabling its use in detergent-sensitive analytical and preparative applications. Furthermore, the detergent-free nature of the above reagent eliminates the risk of detergent-related extraction and leaching of contaminants from packaging materials, tubing, containers, and other equipment used in the manufacturing process.

[0818] iv) No biological hazard: The above reagent is formulated using ingredients that are safe for humans and the environment, eliminating potential biological hazard risks associated with the use of, for example, Triton-X100.

[0819] v) Shorter cell lysis process: Optimized cell lysis reagents enable shorter cell lysis and extraction times. This time-saving aspect can lead to significant cost reductions by decreasing the total time required for the production cycle.

[0820] Overall, the improved viral vector extraction efficiency provided by the detergent-free alkaline dissolution reagent of the present disclosure has the potential to significantly impact the manufacturing costs of viral vector-based medicines. By increasing yield and simplifying the production process, these technical and economic advancements have the ability to make viral vector-based therapies more accessible and affordable for patients who need them.

[0821] Example 4: Lysis reagents for whole cell culture lysis and cell pellet lysis

[0822] In Example 4, the lysis reagent according to the present disclosure was used to lyse whole cell cultures and pelletized cells. Specifically, HEK293 cells in suspension culture following the culture and production of AAV2 were utilized for this purpose in accordance with the present disclosure. To lyse the whole cell culture, a 5x or 10x concentrated lysis reagent was typically applied to achieve a concentration comparable to that of the 1x lysis reagent of the preceding example. For the lysis of the cell pellet, an equivalent amount of whole cell culture was first centrifuged at 300 g for 5 minutes, and the supernatant was removed. The resulting cell pellet was then applied to the 1x lysis reagent to ensure that the concentration of the components in the cell lysis reagent was comparable between the whole cell culture and the cell pellet. The cell lysis reagents according to the present disclosure applied are listed in Table 4 below. As demonstrated below, the lysis reagent disclosed herein addresses technical problems typically encountered in cell lysis, including low cell lysis efficiency and / or long lysis duration, high AAV vector agglutination, and the potential need for physical or mechanical lysis steps (e.g., freeze-thaw cycle(s)). In addition, it is demonstrated below that the lysis reagent according to the present disclosure is applicable to various sample types, such as cell culture media and cell pellets, enabling consistent results. This is particularly advantageous since different types of viral vectors may exist primarily inside, outside, or both of the cell. By allowing applicability to different sample types, the lysis reagent is suitable for intracellular and / or extracellular viral vectors.

[0823]

[0824]

[0825] AAV2 functional titer in cell culture medium

[0826] AAV2 functional titers were determined using the aforementioned incucyte-based transduction assay after cell lysis and clarification of the whole cell culture. For comparison, the "prior art cell lysis reagent" was used as the reference lysis reagent, and CelLytic™ M (C1), CelLytic™ MT (C2, both from Sigma Aldrich), and M-PER (C3, Thermo Fisher Scientific) lysis reagents were also used. The results are shown in Figure 11.

[0827] As can be seen in Fig. 11, the dissolution reagents for CelLytic™ M (C1), CelLytic™ MT (C2), and M-PER (C3) are 0.5 x 10 6 It exhibited very low functional potency of less than TU / mL. Since these lysis reagents are indicated to be suitable only for cell pellets, these results were expected. On the other hand, the "prior art cell lysis reagent (see N82)" also approximately 4x10 6 It resulted in a relatively low functional potency of TU / mL. The reagent of the present disclosure is nearly 10 7 It was possible to obtain a functional potency of TU / mL.

[0828] AAV2 capsid titer in cell culture medium

[0829] Capsid AAV2 titers were determined using the aforementioned Octet® AAVX biosensor after cell lysis and clarification of the total cell culture medium. For comparison, the "prior art cell lysis reagent" was used as the reference lysis reagent, and CelLytic™ M (C1), CelLytic™ MT (C2, both from Sigma Aldrich), and M-PER (C3, Thermo Fisher Scientific) lysis reagents were also used. The results are shown in Figure 12.

[0830] As can be seen in Fig. 12, the CelLytic™ M (C1), CelLytic™ MT (C2), and M-PER (C3) lysis reagents did not yield any measurable capsid titers. Since these lysis reagents are indicated to be suitable only for cell pellets, this result was expected. On the other hand, the "prior art cell lysis reagent" (see N82) also yielded approximately 3 x 10 11 It resulted in a relatively low capsid titer of capsid / mL. The reagent of the present disclosure yielded up to 7x10 11 Capsid / mL was made available.

[0831] Overall, the above results show that the lysis reagent according to the present disclosure is not only well applicable to cell culture media but also leads to increased capsid potency, demonstrating beneficial effects and more efficient cell lysis.

[0832] AAV2 functional titer in cell pellets

[0833] AAV2 functional titers were determined using the aforementioned Incucyte-based transduction assay after cell lysis and clarification of the cell pellet. For comparison, the "prior art cell lysis reagent" was used as the reference lysis reagent, and CelLytic TM M(C1), CelLytic TM MT (C2, both Sigma Aldrich) and M-PER (C3, Thermo Fisher Scientific) dissolution reagents were also used. The results are shown in Figure 13.

[0834] As can be seen in Fig. 13, CelLytic TM M(C1) and M-PER(C3) lysis reagents are 0.5 x 10⁻⁶, like the "prior art cell lysis reagents" (see N98). 6 It exhibited a very low functional potency of less than TU / mL. CelLytic TM Only MT(C2) is about 4x10 6It exhibited a measurable functional potency of TU / mL. The reagent of the present disclosure is approximately 6 x 10⁻⁶ 6 It was possible to obtain a functional potency of TU / mL.

[0835] AAV2 capsid titer in cell pellets

[0836] Capsid AAV2 titers were determined using the aforementioned Octet® AAVX biosensor after cell lysis and clarification of the cell pellet. For comparison, the "prior art cell lysis reagent" was used as the reference lysis reagent, and CelLytic TM M(C1), CelLytic TM MT (C2, both Sigma Aldrich) and M-PER (C3, Thermo Fisher Scientific) dissolution reagents were also used. The results are shown in Figure 14.

[0837] As can be seen in Fig. 14, CelLytic TM The M(C1) and M-PER(C3) lysis reagents did not yield any measurable capsid titers, similar to the "prior art cell lysis reagents" (see N98). CelLytic TM Only MT(C2) is about 6x10 11 Measurable capsid titers of capsid / mL were shown. The reagents of the present disclosure are up to 7.5 x 10⁻⁶ 11 Capsid / mL was made available.

[0838] Overall, the above results show that the lysis reagent according to the present disclosure is not only well applicable to cell pellets but also leads to increased capsid and functional potency, demonstrating beneficial effects and more efficient cell lysis.

[0839] A beneficial but not essential ingredient

[0840] Additionally, the data illustrated in FIGS. 11, 12, 13, and 14 indicate that the functional and capsid potencies obtained with lysis reagents without sucrose, i.e., without cryoprotectants (see N80, N81, N96, and N97), are essentially similar to those achieved with lysis reagents containing sucrose (see N78, N79, N94, and N95). These results highlight that cryoprotectants, such as sugars like sucrose, are added only optionally to the lysis reagents according to the present disclosure. Specifically, they are added to improve the shelf life and freezing of the virus vector-containing composition after lysis and / or purification. However, cryoprotectants do not need to be added for cell lysis. As optional compounds of the lysis reagent, this may be advantageous to avoid subsequent steps (e.g., after cell lysis and / or purification) of adding cryoprotectants, such as sugars like sucrose.

[0841] Furthermore, regarding the detergent polysorbate 20, it was observed that for both whole culture lysis and cell pellet lysis, the inclusion of polysorbate 20 under different lysis conditions resulted in capsid and functional potency up to 30% higher. An additional benefit of polysorbate 20 is its ability to prevent cavitation effects during subsequent downstream processes, such as filtration, thereby reducing the risk of product loss.

[0842] Filterability and pH of the dissolved composition according to the present disclosure

[0843] 10x concentrated acidic and alkaline lysis reagents were first applied to the whole cell culture to achieve a final concentration of 1x lysis reagent. Subsequently, the specific nucleases listed in Table 4 were added, and the mixture was incubated for 1 hour. After incubation, the filterability and pH of the crude lysis composition were evaluated. The results are shown in Table 5 below:

[0844]

[0845] Table 5 illustrates how the filtration properties of crude lysis compositions can vary depending on cell lysis conditions. These variations are associated with different cell lysis efficiencies and changes in host cell impurities. Acidic lysis reagents N70 to N77 resulted in excellent filtration properties and were therefore classified into Group A. In contrast, alkaline lysis reagents exhibited good to moderate filtration properties. In particular, N78 (Figs. 11 and 12), identified as the most efficient lysis reagent in this disclosure, exhibited moderate filtration properties.

[0846] conclusion

[0847] Example 4 demonstrates that the lysis reagent according to the present disclosure leads to consistently high capsid and functional potency for different types of cell culture samples. Specifically, it was shown that the lysis reagent of the present disclosure can be used in whole cell culture media and cell pellets. A comparison of cell lysis efficiencies for the alkaline reagents exhibiting the best performance yields the following results:

[0848] - Basic reagent: 100% (cell culture medium) and 100% (cell pellet)

[0849] - Acidic reagent: ~80% (cell culture medium) and ~45% (cell pellet)

[0850] - Prior art reagents: ~45% (cell culture medium) and ~0% (cell pellet)

[0851] - CelLytic TM MT: ~0% (cell culture medium) and ~80% (cell pellet)

[0852] Accordingly, the cells may undergo a separation step from the surrounding liquid (e.g., by centrifugation / sedimentation and removal of the supernatant), or a cell culture medium without any processing step may be used. This is particularly advantageous in that the cell lysis reagent of the present disclosure can be used flexibly with broad applicability. Furthermore, such applications allow the cell lysis reagent according to the present disclosure to be used on-site ( in situ ) can be used, that is, the cell lysis reagent can be added directly to a culture vessel, such as a bioreactor or shaking flask, after the production of a viral vector, for example, AAV.

[0853] Example 5: The dissolving reagent is effective and non-toxic.

[0854] In Example 5, the efficacy of the Triton X-100-containing lysis reagent and the lysis reagent of the present disclosure was evaluated for the lysis of whole cell cultures. Although the Triton X-100-containing reagent is known to be effective and has historically been widely used for cell lysis and intracellular product extraction, its use has been restricted because Triton X-100 is listed on the REACH list of substances of high concern by the European Union—that is, a list of substances whose use must be avoided to protect human health and the environment from risks that may be caused by chemicals. For the lysis of whole cultures, suspension cultures of HEK293 cells following the culture and production of AAV2 were utilized for this purpose in accordance with the present disclosure. Typically, for example, 5x or 10x concentrated lysis reagents were applied to achieve concentrations comparable to the 1x lysis reagent of the preceding example. The cell lysis reagents according to the present disclosure applied are listed in Table 6 below. As demonstrated below, the lysis reagents disclosed herein address technical problems typically encountered in cell lysis, including low cell lysis efficiency and / or long lysis duration, high AAV vector aggregation, and the potential need for physical or mechanical lysis steps (e.g., freeze-thaw cycles).

[0855]

[0856] Functional titers of AAV2 in cell culture medium for different lysis reagents

[0857] AAV2 functional titers were determined using the aforementioned incucyte-based transduction assay after cell lysis and clarification of the whole cell culture medium. For comparison, the "prior art cell lysis reagent" was used as the reference lysis reagent, and a lysis reagent containing Triton X-100 was also used. The results are shown in Figure 15.

[0858] As shown in FIG. 15, the reagent of the present disclosure is up to 9x10 6 While it made it possible to obtain TU / ml, the "prior art cell lysis reagent (see N82) is 4x10 6 TU / ml was obtained. The Triton X-100-containing cell lysis reagent (see TNT), whose use is restricted due to the cytotoxicity mentioned earlier and further exemplified later, is limited to a maximum of 7x10 6 As TU / ml, it exhibited efficiency equivalent to that of the reagent disclosed in this example. Therefore, the above results indicate that the lysis reagent according to the present disclosure enables highly efficient cell lysis and increased functional potency yield without containing any cytotoxic components.

[0859] AAV2 capsid titers in cell culture medium for different lysis reagents

[0860] Capsid AAV2 titers were determined using the aforementioned Octet® AAVX biosensor after cell lysis and clarification of the entire cell culture medium. For comparison, the "prior art cell lysis reagent" was used as the reference lysis reagent, and a lysis reagent containing Triton X-100 was also used. The results are shown in Figure 16.

[0861] As shown in FIG. 16, the reagent of the present disclosure is up to 9x10 11While it made it possible to obtain capsid / ml, "prior art cell lysis reagents (see N82) were nearly 4x10 11 Capsid / ml was obtained. A commonly used Triton X-100-containing cell lysis reagent (see TNT), whose use is limited due to the cytotoxicity mentioned earlier and further exemplified later, is approximately 8 x 10 11 As capsid / ml, it exhibited efficiency equivalent to that of the reagent disclosed in this example. Therefore, the above results indicate that the lysis reagent according to the present disclosure enables highly efficient cell lysis and increased capsid potency yield without containing any cytotoxic components.

[0862] Toxicity test

[0863] To investigate the potential toxic effects of Triton X-100 compared to the detergent used in the lysis reagent according to the present disclosure, AAV crude cell lysis compositions derived using Triton X-100 or polysorbate 20-containing lysis reagents as outlined in Table 6 were first diluted to a 1x concentration in the final crude lysate after a sterile filtration step. This was then further diluted in the range of 1:10 to 1:320. The resulting diluted samples were applied to adherent HEK293 cells according to the transfection analysis protocol described above. Subsequently, the phase contrast confluence of these cells was analyzed using an Incucyte® Live-Cell Analysis system. The results are shown in Fig. 17.

[0864] The obtained phase-contrast-based cell density in Fig. 17 shows that the cells are dramatically affected by the presence of Triton X-100 (see TRT), with the phase-contrast-based cell density decreasing from over 90% to 12%. In contrast, whether the buffer composition was acidic or alkaline (see N70A, N74A, or N78A), there was no decrease in cell density even at the highest concentration of Tween 20, and it remained high at 94%. The above results demonstrate the strong cytotoxic effect of Triton X-100 on cells.

[0865] conclusion

[0866] Example 5 demonstrates that the lysis reagent according to the present disclosure leads to consistently high capsid and functional potency for different types of cell culture media, enabling similar results (or improvements in some cases) compared to Triton X-100-based lysis reagents. On the other hand, Triton X-100-based lysis reagents are toxic and cause subsequent problems in waste management as well as in the purification of viral vectors. On the other hand, the polysorbate-based lysis reagent used herein does not cause these concerns, making it advantageous for safety and waste management reasons.

[0867] Example 7: Cell lysis for AAV8

[0868] In Example 7, HEK293 cells producing AAV8 were lysed using a single-step protocol as described herein. This example demonstrates that the lysis approach is applicable to other AAV serotypes (compared to Examples 1 through 6, in which AAV2 was produced). The lysis approach yielded high AAV8 titers while maintaining low levels of host cell-associated impurities. Thus, the cell lysis approach is widely applicable and efficient for obtaining large quantities of pure viral vectors.

[0869] For this example, HEK293 cells were transiently transfected with a plasmid to produce AAV8 having a GFP-coding sequence as a transplant gene. After the production of AAV8, 9 mL of cell culture medium was mixed with each of the reagents listed in Table 7. As another criterion, the cell pellet was lysed. Since most of the AAV8 is secreted into the culture medium and only a very small amount of the viral vector remains inside the cell, this example demonstrates that a sufficient amount of AAV8 cannot be obtained using conventional lysis approaches applicable to cell pellets.

[0870]

[0871] After lysis, TCC, cell viability ratio, and cell diameter were analyzed for the samples, and pH was also measured. Subsequently, the crude lysed samples were centrifuged (5,000 xg, 5 min), and DNA, HCP, and AAV8 capsid titers were measured. The results are presented in Table 8.

[0872]

[0873] The results in Table 8 show that most AAV8 is present in the supernatant, as the capsid titer for cell cultures (a, b) is significantly higher than after lysis of the cell pellet (i). Without lysis, the viability of the cell culture references remained almost unchanged during the experiment (69.6% initially in a and 68% in b after 60 minutes). For the lysis approach at pH 8 (see d), viable cells were measured even after 60 minutes of incubation (1.2%), indicating incomplete cell lysis. All other conditions resulted in essentially complete lysis. The pH measured in the above compositions is approximately pH 8 (d) or approximately pH 4 (c, e).

[0874] Due to the high AAV8 capsid titer in the undissolved cell culture supernatant (see a and b), only a small increase in AAV8 titer was achieved by cell lysis. Nevertheless, the above model process can be used to obtain some information regarding the efficiency of cell lysis and the release or reduction of impurities.

[0875] Overall, the highest AAV8 capsid titer was measured for a single-step, pH 8 dissolution, but this was the highest impurity level (1.14 x 10⁻⁶). 4 μg / L HCP and 9.36x10 2 It was with μg / L DNA). Meanwhile, single-step pH 4 dissolution yielded low AAV8 levels close to the reference substance (see c compared with a, b), but the impurity levels for DNA and HCP were low.

[0876] In conclusion, the above examples demonstrate the applicability of the cell lysis approach of the present disclosure to different AAV serotypes, which indicates applicability to different viral vectors.

[0877] Example 8: Applicability of the cell lysis approach to adenoviruses

[0878] In Example 8, different lysis protocols were applied to cell cultures producing adenovirus (Ad) and various parameters were measured. The above example demonstrates that the lysis method according to the present disclosure is applicable to Ad-producing host cells, consistently achieves high Ad yields, and maintains host cell-related impurities at low levels.

[0879] In this embodiment, 25.6x10 6Cell culture medium of HEK293 cells producing adenovirus with a TCC of cells / mL and a viability of 80.4% was used. For each lysis condition, 27 mL of cell culture medium was lysed in 3 mL of 10x lysis reagent in a 50 mL tube and incubated at 37°C in an incubator. The tube was placed on a disc rotator to achieve mixing. After 90 minutes, some lysis conditions required the addition of an acidifying reagent or salt. After 120 minutes, sampling was performed, and different characteristics were measured. The lysis conditions disclosed in Table 9 were applied.

[0880]

[0881] Changes in cell culture medium characteristics due to lysis

[0882] As described above, TCC and survival rates were measured after performing dissolution. The results are shown in Figure 18. Except for reference samples S0 and S1, the survival rates are generally low.

[0883] Effect on capsid titer

[0884] In addition, the capsid titer of Ad was measured for the crudely lysed samples and after 0.2 μm filtration of the samples. As shown in Fig. 19, generally high capsid titers were measured. For single-step cell lysis, pH 4 (see S8), slightly lower capsid titers were obtained. For all other lysis methods, 1.5 to 2 x 10⁻⁶ 12 The capsid potency of capsid / mL was measured. Thus, the cell lysis approach yielded an Ad capsid potency comparable to conventional methods used in the industry (see S2 and S11).

[0885] Effects on DNA and HCP impurities

[0886] In addition, impurities (HCP and DNA) of Ad were measured for the crude dissolved samples and after filtration. In FIGS. 20 and 21, the impurities were established in relation to the achieved titer. As shown in FIGS. 20 and 21, the acidic dissolution approach yielded the lowest HCP content (see S8). In addition, the DNA content was also at a relatively low level. However, in the approach disclosed herein, harmful substances such as Triton X-100 are avoided, which is advantageous since said compounds are harmful to the environment and should be avoided in pharmaceutical compositions, such as viral vector formulations conceived for gene therapy.

[0887] conclusion

[0888] Example 8 demonstrates that the lysis approach is applicable to lysing adenovirus-producing cells and highlights the broad applicability to different viral vectors. Thus, the lysis approach is highly efficient for cell lysis. Furthermore, the results once again emphasize that alkaline lysis reagents maximize yield, while acidic lysis reagents allow for the minimization of host cell-related impurities.

[0889] conclusion

[0890] The above examples demonstrate that the lysis reagent is highly efficient for lysing cells to obtain increased capsid and functional viral vector titers. The lysis reagent is widely applicable to various types of viral vectors as well as to different cell cultures or samples, including cell culture media and cell pellets. This enables the lysis reagent to be applied directly to cell cultures, for example, within culture vessels such as bioreactors or shaking flasks. Furthermore, it was shown that a relatively short incubation time of 0.5 to 3.5 hours is sufficient for cell lysis, thereby improving efficiency. At the same time, the results of the lysis reagent according to the present disclosure exhibited different characteristics. Specifically, the alkaline lysis reagent (detergent, with or without Tween 20 herein) enabled the attainment of maximum capsid and functional titers, wherein the titers are highest at higher salt concentrations, e.g., greater than 50 mM, e.g., 275 mM, 500 mM, and 1000 mM. Furthermore, acidic dissolution reagents yielded higher capsid and functional potencies compared to standard dissolution reagents, but not as high as alkaline dissolution reagents. Meanwhile, acidic dissolution reagents have the advantage of being filterable without the use of nucleases and, in particular, resulting in low host cell-associated impurities. Therefore, while acidic dissolution reagents may not achieve the highest capsid and functional potencies, they resulted in purified viral vectors with fewer impurities compared to alkaline-based dissolution reagents. Additionally, acidic dissolution reagents do not require a nuclease degradation step and thus result in a simplified and less costly dissolution process. Finally, by using dissolution reagents that avoid toxic compounds such as Triton X-100, the detergent-containing dissolution reagents according to the present disclosure, including polysorbate detergents such as Tween 20, achieve reduced toxic side effects and improved waste management.

Claims

Claim 1 A method for releasing a viral vector from a cell culture, the method comprising the following steps: (a) providing a lysis reagent comprising a buffer having a concentration of 0.01 M to 3 M and a salt having a concentration of 0.01 M to 5 M; (b) bringing the cell culture into contact with the lysis reagent to produce a lysis composition; and (c) incubating the lysis composition so that the viral vector is released from the cell culture, wherein, in step (b), the cells of the cell culture do not need to be separated from the surrounding liquid before bringing the cell culture into contact with the lysis reagent. Claim 2 The method of claim 1, wherein the cell culture is a cell culture medium or a cell pellet, preferably a cell culture medium. Claim 3 In one or more of claim 1 or 2: I. The buffer solution has a concentration selected from the following range: - 0.05 M to 1 M for 1x dissolving reagent; - 0.3 M to 1.5 M for 5x dissolution reagent; or - Preferably, 1 M to 3 M for a 10x dissolving reagent; and / or II. Method, wherein the salt has a concentration selected from the following range: - 0.05 M to 1 M for 1x dissolving reagent; - 0.3 M to 1.5 M for 5x dissolution reagent; or - Preferably, for the 10x dissolving reagent, 0.8 M to 5 M or 1 M to 3 M. Claim 4 In one or more of claims 1 to 3, the dissolving reagent is a divalent cation, preferably Mg 2+ , Ca 2+ , Ba 2+ , Cu 2+ , Fe 2+ , Zn 2+ , Mn 2+ , Ni 2+ or a combination thereof, more preferably Mg 2+ , Cu 2+ , Zn 2+ , Mn 2+ , Ni 2+ or a combination thereof, most preferably Mg 2+ Method comprising at a concentration of 0.1 mM to 100 mM, preferably having a concentration selected from the following range: i) ii) 0.5 mM to 5 mM for the 1x dissolution reagent; 5 mM to 15 mM for the 5x dissolution reagent; or iii) preferably, 15 mM to 50 mM for the 10x dissolution reagent. Claim 5 A method according to one or more of claims 1 to 4, wherein the dissolving reagent is an acidic dissolving reagent, preferably having a pH of less than 6.0, preferably less than 5.0, and most preferably less than 4.

5. Claim 6 In claim 5, the dissolved composition in step (b) is: i) ii) pH is less than 5.0, preferably less than 4.5 and / or A method in which the pH is selected from the range of 2.5 to 5.0, preferably 3.5 to 4.

5. Claim 7 A method according to one or more of claims 1 to 4, wherein the dissolving reagent is an alkaline dissolving reagent, preferably having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, e.g., 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, or greater than 8.

5. Claim 8 A method according to claim 7, wherein in step (b), the dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.

0. Claim 9 Method according to one or more of claims 1 to 8, wherein the dissolving reagent comprises a detergent, preferably a nonionic detergent, more preferably a nonionic detergent that is non-toxic to the environment and / or not harmful to the environment, at a concentration of 0.1% (v / v) to 20% (v / v), preferably selected from the following range: i) ii) For 1x dissolution reagent, 0.1% (v / v) to 2% (v / v); 1% (v / v) to 5% (v / v) for 5x dissolution reagent; or iii) For 10x dissolution reagent, 4%(v / v) to 10%(v / v). Claim 10 Method according to one or more of claim 1 or claim 9, wherein the dissolving reagent is one of the following: i) an acidic dissolving reagent selected from the following: I. a 1x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer or a glycine buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar; II. a 5x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following: - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer or a glycine buffer; - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar; or III. a 10x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following: - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer or a glycine buffer; - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar; ii) an alkaline dissolving reagent containing a detergent selected from the following: I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar; II. a 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar; or III. a 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar; or iii) a detergent-free alkaline dissolving reagent selected from the following: I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar; II. a 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride; - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 10% (v / v) to 35% (w / v), preferably a sugar; or III. a 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 1 M to 3 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride; - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 20% (w / v) to 60% (w / v), preferably a sugar. Claim 11 Method of one or more of claims 1 to 10, wherein in step (b), the dissolving composition essentially comprises a compound at a concentration of 1x dissolving reagent, preferably essentially at a concentration according to claim 10, and / or the dissolving composition has one of the following characteristics: I. The dissolving composition has a pH of less than 5.0, preferably less than 4.5, and comprises: - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer or a glycine buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar; II. The dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0, and comprises the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar; or III. The dissolved composition has a pH greater than 7.2, preferably greater than 7.5, most preferably greater than 7.8 or 8.0, and comprises the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably tris(hydroxymethyl)-aminomethane (TRIS) buffer or 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a cryoprotectant having a concentration selected from 1% (w / v) to 10% (w / v), preferably a sugar. Claim 12 In one or more of claims 1 to 11, the method has one or more of the following features: i) The incubation step (c) comprises incubating for less than 6 hours, preferably less than 5 hours or less than 4 hours, more preferably less than 3 hours, e.g., 2 hours, 1 hour, or 0.5 hours; ii) When the cell culture is a cell culture medium, significant yields of capsid viral vector titers and / or transduction viral vector titers are obtained, wherein the significant amount is at least 1 x 10⁶ per mL. 11 Capsid and / or 1 x 10⁶ per mL 6 TU;iii) The above viral vector is primarily present within cells and is preferably selected from adeno-associated virus (AAV) or adenovirus (Ad); and / or iv) The cell culture comprises mammalian cells, preferably mammalian cells selected from HEK293 cells or derivatives of HEK293 cells. Claim 13 In one or more of claims 1 to 12, the method has the following features: i) The cell culture comprises mammalian cells, preferably mammalian cells selected from HEK293 cells or derivatives of HEK293 cells; ii) The incubation step (c) includes incubating for less than 4 hours, preferably less than 2 hours; and iii) The above dissolving reagent does not contain Triton X-100, and preferably, the above dissolving reagent does not contain any nonionic detergents that are toxic to the environment and / or harmful. Claim 14 A method for producing a viral vector, the method comprising the following steps: x.1 providing a cell culture capable of producing a viral vector; x.2 culturing the cell culture to produce a viral vector; x.3 releasing the viral vector from the cell culture according to one or more of claims 1 to 13; and x.4 optionally, purifying the released viral vector. Claim 15 A method according to claim 14, wherein at least one of steps x.2 and x.3 is performed in a bioreactor, preferably both steps x.2 and x.3 are performed in a bioreactor. Claim 16 A cell lysis reagent for releasing a viral vector from a cell culture, preferably from a cell culture medium, selected from one of the following: i) an acidic lysis reagent selected from the following: I. a 1x acidic lysis reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably an acetate buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose; II. a 5x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following: - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably an acetate buffer; - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose; or III. a 10x acidic dissolving reagent having a pH of less than 6.0, preferably less than 5.0, most preferably less than 4.5, and comprising the following: - A buffer having a concentration selected from 1 M to 3 M, preferably an acetate buffer; - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose; ii) an alkaline dissolving reagent containing a detergent selected from the following: I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 0.1% (v / v) to 2% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose; II. a 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer; - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 1% (v / v) to 5% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose; or III. a 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer; - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride; - A detergent having a concentration selected from 4% (v / v) to 10% (v / v), preferably a polysorbate; - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose; or iii) a detergent-free alkaline dissolving reagent selected from the following: I. 1x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.05 M to 1 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer; - A salt having a concentration selected from 0.05 M to 1 M, preferably potassium chloride or sodium chloride; - Optionally, a divalent cation having a concentration selected from 0.5 mM to 5 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 1% (w / v) to 10% (w / v), preferably sucrose; II. a 5x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 0.3 M to 1.5 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer; - A salt having a concentration selected from 0.3 M to 1.5 M, preferably potassium chloride or sodium chloride; - Optionally, a divalent cation having a concentration selected from 5 mM to 15 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 10% (v / v) to 35% (w / v), preferably sucrose; or III. a 10x alkaline dissolving reagent having a pH greater than 7.0, preferably greater than 7.5, most preferably greater than 7.7, and comprising the following: - A buffer having a concentration selected from 1 M to 3 M, preferably a tris(hydroxymethyl)-aminomethane (TRIS) buffer; - A salt having a concentration selected from 0.8 M to 5 M or 1 M to 3 M, preferably potassium chloride or sodium chloride; - Optionally, a divalent cation having a concentration selected from 15 mM to 50 mM, preferably Mg 2+ ; and - Optionally, a sugar having a concentration selected from 20% (w / v) to 60% (w / v), preferably sucrose. Claim 17 A kit for releasing a viral vector from a cell culture, preferably from a cell culture medium, wherein the kit comprises a container containing a cell lysis reagent according to claim 16, and preferably one or more of the following: (i) (ii) mammalian cells, preferably selected from HEK293 cells or derivatives of HEK293 cells; One or more plasmids for producing a viral vector; (iii) Transfection reagent; and / or (iv) Cell culture medium.